

# *Circulating bile acids as a link between the gut microbiota and cardiovascular health: impact of prebiotics, probiotics and polyphenol-rich foods*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Pushpass, R.-A. G., Alzoufairi, S., Jackson, K. G. ORCID: <https://orcid.org/0000-0002-0070-3203> and Lovegrove, J. A. ORCID: <https://orcid.org/0000-0001-7633-9455> (2022)  
Circulating bile acids as a link between the gut microbiota and cardiovascular health: impact of prebiotics, probiotics and polyphenol-rich foods. *Nutrition Research Reviews*, 35 (2). pp. 161-180. ISSN 0954-4224 doi: 10.1017/S0954422421000081  
Available at <https://centaur.reading.ac.uk/100078/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1017/S0954422421000081>

Publisher: Cambridge University Press

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in

the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

# Circulating bile acids as a link between the gut microbiota and cardiovascular health: impact of prebiotics, probiotics and polyphenol-rich foods

Rose-Anna G. Pushpass, Shouq Alzoufaiir, Kim G. Jackson and Julie A. Lovegrove\*

*Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, and Institute for Cardiovascular and Metabolic Research, University of Reading, Harry Nursten Building, Whiteknights, Pepper Lane, Reading, RG6 6DZ, UK*

## Abstract

Beneficial effects of probiotic, prebiotic and polyphenol-rich interventions on fasting lipid profiles have been reported, with changes in the gut microbiota composition believed to play an important role in lipid regulation. Primary bile acids, which are involved in the digestion of fats and cholesterol metabolism, can be converted by the gut microbiota to secondary bile acids, some species of which are less well reabsorbed and consequently may be excreted in the stool. This can lead to increased hepatic bile acid neo-synthesis, resulting in a net loss of circulating low-density lipoprotein. Bile acids may therefore provide a link between the gut microbiota and cardiovascular health. This narrative review presents an overview of bile acid metabolism and the role of probiotics, prebiotics and polyphenol-rich foods in modulating circulating cardiovascular disease (CVD) risk markers and bile acids. Although findings from human studies are inconsistent, there is growing evidence for associations between these dietary components and improved lipid CVD risk markers, attributed to modulation of the gut microbiota and bile acid metabolism. These include increased bile acid neo-synthesis, due to bile sequestering action, bile salt metabolising activity and effects of short-chain fatty acids generated through bacterial fermentation of fibres. Animal studies have demonstrated effects on the FXR/FGF-15 axis and hepatic genes involved in bile acid synthesis (CYP7A1) and cholesterol synthesis (SREBP and HMGCR). Further human studies are needed to determine the relationship between diet and bile acid metabolism and whether circulating bile acids can be utilised as a potential CVD risk biomarker.

**Key words:** Bile acids: Prebiotics: Probiotics: Polyphenols: Cardiovascular disease: Gut microbiota

(Received 3 June 2020; revised 24 March 2021; accepted 5 April 2021)

## Introduction

Cardiovascular diseases (CVD) are a major cause of mortality and disability in the UK <sup>(1)</sup>. Since diet and low-density lipoprotein (LDL)-cholesterol (LDL-C) are both important modifiable CVD risk markers, there is considerable interest in dietary strategies which can reduce LDL-C levels for disease prevention <sup>(2)</sup>. Probiotic, prebiotic and polyphenol-rich interventions have reported beneficial effects on the fasting lipid profile, with changes in the gut microbiota composition thought to play an important role in lipid regulation. Emerging evidence suggests that bile acids may act as a link between changes in the gut microbiota and cardiovascular health, via effects on circulating lipids, inflammation and glycaemia, with the profile and concentration of circulating bile acids considered to be a potential novel biomarker of disease risk <sup>(3)</sup>.

Bile acids are synthesised in the liver from cholesterol and form the major component of bile <sup>(3)</sup>. They are stored in the gall-bladder before being released into the gut in response to food intake, where they emulsify dietary fats to facilitate adsorption of lipids and lipid-soluble vitamins <sup>(4)</sup>. Bile acids are significantly modified in the gut by bacterial enzymes <sup>(5)</sup>. Bile salt hydrolase (BSH), bile acid inducible (BAI) and bile acid dehydratase enzymes, expressed by certain species of gut bacteria can

modify bile acids to generate unconjugated and secondary bile acids <sup>(6)</sup>. These converted bile acids may be less well absorbed in the intestine, and as such, the proportion of bile acids being excreted may be affected by the microbial population in the gut <sup>(7)</sup>. The vast majority (95 %) of bile acids are recycled back to the liver via the hepatic portal circulation in what is known as the enterohepatic cycle <sup>(8)</sup>. However, a small percentage will escape recycling and are excreted in the faeces. Bile acid neo-synthesis is an effective system for cholesterol regulation in the body, taking cholesterol out of the circulation to be used for synthesis of new bile acids, replacing those lost in the faeces. Certain foods including probiotics, prebiotics and those rich in polyphenols have been shown to alter the gut microbiome, enhancing growth of probiotic bacteria with bile acid metabolising activity. Since high circulating LDL-C levels are a significant risk factor for CVD <sup>(9)</sup>, the ability of probiotic bacteria to reduce cholesterol via bile acid modification in the gut could be key for dietary interventions in reducing disease risk and improving population health. This narrative review will provide an overview of bile acid metabolism and determine the role of probiotics, prebiotics and polyphenol-rich foods in modulating circulating bile acids and lipid risk markers for CVD.

\* Corresponding author: Julie A Lovegrove, email: [j.a.lovegrove@reading.ac.uk](mailto:j.a.lovegrove@reading.ac.uk)

## Bile acids and modulation of CVD risk markers

Bile acids are synthesised through two distinct pathways, the classical and alternative pathways (see Fig. 1 for an overview). For an in-depth discussion on the synthesis of bile acids, the reader is directed to an excellent review by Li and Chiang<sup>(10)</sup>. Within the liver, classic bile acid synthesis is initiated in the hepatocytes via cholesterol hydroxylation, catalysed by the cholesterol 7 $\alpha$ -hydroxylase (CYP7A1) enzyme, part of the cytochrome P450 enzyme family<sup>(11)</sup>. This is the rate-limiting step in bile acid synthesis and leads to conversion of cholesterol to 7 $\alpha$ -hydroxycholesterol. CYP7A1 expression is regulated by farnesoid X receptor (FXR), via a feedback mechanism, by an increase in bile acids following food intake. FXR can be directly activated in hepatocytes or by bile acids in the gastro-intestinal (GI) tract. In the intestine, FXR activation leads to expression of fibroblast growth factor (FGF) 19, which travels to the liver to activate FGF receptor 4 (FGFR4) and ultimately suppresses expression of CYP7A1, inhibiting bile acid synthesis<sup>(10)</sup>. The alternative bile acid pathway occurs in the mitochondria and produces mainly chenodeoxycholic acid, and can therefore theoretically occur in all cell/tissue types. Evidence of alternative bile acid synthesis has been shown to occur in the brain, macrophages and liver<sup>(12–14)</sup>. In this pathway, hydroxylation of cholesterol leads to its conversion to oxysterols catalysed by sterol 27-hydroxylase. 7 $\alpha$ -hydroxylated oxysterols are eventually converted to primary bile acids in enzymatic pathways common to both the classic and alternate bile acid pathways (Fig. 1)<sup>(15)</sup>. In the final step of bile acid synthesis, bile acids are conjugated to an amino acid, either glycine or taurine, via formation of a thioester intermediate, which is catalysed by the bile acid cholesteryl-CoA synthetase and bile acid CoA:amino acid *N*-acyltransferase enzymes<sup>(16,17)</sup>. Conjugated bile acids, known as bile salts, have greater water solubility and are secreted into bile which is stored in the gallbladder. The hormone cholecystokinin is the main regulator of gallbladder contraction and sphincter of Oddi relaxation which facilitates the release of bile through the bile duct and duodenal papilla to the duodenum during the post-prandial phase<sup>(18,19)</sup>. Following food intake, nutrients, including fatty acids and some amino acids, are sensed in the small intestine (the duodenum), resulting in secretion of cholecystokinin by enteroendocrine cells and promoting absorption in the intestine<sup>(20)</sup>.


Sterol regulatory element-binding proteins (SREBP) belong to a family of basic helix-loop-helix leucine-zipper transcription factors which are regulated by intracellular levels of cholesterol/oxysterols and are vital in the regulation of fatty acid and cholesterol synthesis<sup>(21)</sup>. SREBP-1c (produced from the SREBF-1 gene) is mainly involved in fatty acid synthesis, while SREBP-2 (encoded by the SREBF-2 gene) is implicated in the synthesis of cholesterol<sup>(10,22)</sup>. SREBP-1c expression is induced by insulin as well as activation of liver X receptor (LXR)- $\alpha$  by oxysterols<sup>(23)</sup> required to generate fatty acids for the synthesis of cholesterol esters<sup>(24)</sup>. Transcription factors for SREBP2 are preserved as an inactive precursor in the endoplasmic reticulum membranes when oxysterol levels are high, for example during synthesis of bile acids. However, conversion of intracellular oxysterols to primary bile acids leads to transportation of the SREBP2 precursor to the Golgi apparatus where it is cleaved by proteases

to release the amino-terminal portion of the protein from its membrane-bound precursor. This protein then migrates to the nucleus where it can activate the transcription of the LDL-receptor gene, increasing the expression of receptors on the surface of the hepatocytes and leading to an increase in intracellular cholesterol levels<sup>(22)</sup>. Interestingly, studies in mice have shown that overexpression of CYP7A1 leads to increased hepatic expression of SREBP2, suggesting a link between bile acid synthesis and hepatic cholesterol regulation<sup>(25)</sup>.

Enterohepatic circulation allows for recycling of bile acids and other substances that are absorbed from the intestine, packaged as lipid micelles, and transported back to the liver via portal blood circulation (see Fig. 2 for an overview)<sup>(8)</sup>. In addition, some free hydrophobic bile acids are reabsorbed by passive diffusion in the GI tract. Once in the liver they are secreted into the bile and subsequently re-enter the intestine. A large proportion (95 %) of bile acids are recycled in this way, with the remaining 5 % being excreted in faeces<sup>(5)</sup>. Enterohepatic recycling is important to preserve the bile acid pool which is vital for many functions of the liver and GI tract such as bile flow, solubilisation and excretion of cholesterol as well as intestinal absorption of lipophilic compounds<sup>(26)</sup>. In addition, this process conserves cholesterol and bile acids for re-use and avoids the loss of these valuable sterols which would otherwise need to be endogenously synthesised or obtained from the diet.


The microbiota residing in the GI tract can influence the proportions of primary and secondary bile acids<sup>(27)</sup>. This is because several species of gut bacteria, including *Clostridium*, *Enterococcus*, *Bifidobacterium*, *Lactobacillus* and members of the genus *Bacteroides*, are capable of converting primary bile acids into secondary bile acids, such as lithocholic acid (LCA) and deoxycholic acid (DCA), via 7 $\alpha$ -dehydroxylation (BAI encoded) enzymes and further conversion into unconjugated forms, in the distal ileum by BSH enzymes (Table 1)<sup>(28)</sup>. In the large intestine, bile acids undergo bacterial bio-transformations including de-conjugation followed by further metabolism such as oxidation of hydroxyl groups and dihydroxylation<sup>(29)</sup>. Secondary bile acids, especially the more hydrophobic ones, are less well absorbed in the enterohepatic cycle, and therefore a greater amount may be excreted in the faeces, leading to a net loss of cholesterol<sup>(3)</sup>. This is because bacterial de-conjugation results in more hydrophobic bile acids which are poorly absorbed via passive diffusion. Table 1 presents the relative hydrophobicity of the main bile acids. LCA is commonly cited as the most hydrophobic bile acid<sup>(30)</sup>; however, the hydrophobicity index for un-conjugated LCA could not be found in the literature. Meanwhile, conjugated bile acids can be more easily taken up by ileal bile acid transporters/apical bile acid transporters (IBAT/ABAT) transporters<sup>(7)</sup>. The secondary bile acids constitute up to 35 % of the circulating bile acids and have important regulatory functions in metabolic processes including weight maintenance and glucose/lipid tolerance<sup>(31)</sup>. As such, the gut microbiota plays an important role in the enterohepatic circulation and cholesterol regulation.

A mechanistic link between gut microbiota composition and host physiology is thought to occur via the microbiologically produced secondary bile acids. These act as key regulators in several metabolic processes since they are considered to be stronger



**Fig. 1.** Metabolism of bile acids: bile acid synthesis occurring in the liver from cholesterol via host cytochrome P450 enzymes, through the classic and alternative bile acid synthetic pathways. Conjugation of bile acids occurs in the liver, with further modification of BA moieties by microbes in the GI tract which can de-conjugate using bile salt hydrolases (BSH). This results in free primary bile acids which can be further modified by microbes for example dehydroxylation via bile acid-inducible (BAI) enzymes to yield a variety of secondary bile acids (such as deoxycholic and lithocholic acid). Reprinted from Molecular Aspects of Medicine, 56, Sarah L. Long, Cormac G.M. Gahan, Susan A. Joyce, Interactions between gut bacteria and bile in health and disease, Pages No. 54–65, Copyright (2017), with permission from Elsevier.





**Fig. 2.** Enterohepatic circulation of cholesterol and bile acids: between 0.2 and 0.6 g bile acid is synthesised per day in the liver to maintain the human bile acid pool which is made up of approximately 3 g of bile acids. Absorption of nutrients following food intake results in stimulation of the gallbladder, which releases bile acids into the small intestine. In the ileum, conjugated bile acids can be easily reabsorbed by active transport, while a small amount of unconjugated bile acids are reabsorbed by passive diffusion in the small and large intestines. Bile acids are then extracted from the portal blood by the liver. Small amounts of bile acids are excreted in the faeces (approximately 5 %) and must be replaced by neo-synthesis in the liver.

agonists for several receptors involved in host metabolism compared with primary bile acids<sup>(32)</sup>. Bile acids activate specific nuclear receptors including FXR, vitamin D receptor (VDR), pregnane X receptor (PXR) and the G-protein-coupled receptor TGR5 which are implicated in cell signalling pathways in both the liver and the GI tract (see Table 1 for signalling potential of common bile acids)<sup>(33)</sup>. FXR activation has been linked to the maintenance of normal triacylglycerol (TAG) and cholesterol levels, as well as regulating factors in the liver and intestine which influence CVD risk such as lipid and glucose homeostasis, endothelial function and atherosclerosis<sup>(34)</sup>. Meanwhile, the secondary bile acids LCA and DCA act as powerful ligands for TGR5<sup>(35)</sup>. This influences several important metabolic pathways, such as thermogenesis, energy metabolism and glucose homeostasis. Activation of TGR5 leads to increased intestinal production of the gut hormone glucagon-like peptide (GLP)-1 promoting insulin secretion and regulation of appetite, and increased energy expenditure via conversion of thyroid hormone T4 into the active form, T3<sup>(36,37)</sup>.

The profile of secondary bile acids, both in the GI tract and systemically, may differ in conjunction with improved and diminished host health. For instance, in animal models, increased circulating levels of taurocholate have been associated with greater proliferation of the gut bacteria *Bilophila wadsworthia*, which are related to inflammatory bowel disease<sup>(38)</sup>. Higher serum concentrations of DCA, a secondary bile acid produced via colonic microbial transformation of cholic acid, have been found in obese mice, likely due to dysbiosis of the gut microbiota such as a proliferation of clostridium species<sup>(39)</sup>. Meanwhile levels of other secondary bile acids may be linked with beneficial effects on host health. For example, increased levels of ursodeoxycholic acid (UDCA) and its glycine and taurine conjugates in bariatric surgery patients have been demonstrated alongside increased insulin sensitivity<sup>(40)</sup>. Furthermore, a study in rats by Basso *et al.*<sup>(41)</sup> found higher levels of UDCA after partial gastrectomy which occurred in conjunction to enhanced insulin sensitivity and fat distribution, independent of weight loss<sup>(41)</sup>. Increased levels of circulating bile acids are also found in Roux-en-Y gastric bypass patients

because, when the duodenum and proximal jejunum are bypassed, bile acids do not mix with food until they reach the mutual portion of the jejunum<sup>(42)</sup>. This means that greater concentrations of bile acids are delivered to the jejunum, and their uptake by IBAT/ABAT transporters is increased in the ileum. As a consequence, higher concentrations of bile acids occur in the portal vein, and more bile acids are released into the systemic circulation. Furthermore, alterations of the gut microbiota are known to occur following bariatric surgery, with a tendency toward reduced Firmicutes-to-Bacteroides ratio and an increase in Proteobacter, which can alter the proportions of secondary bile acids in the intestinal bile acid pool through increased BSH activity<sup>(32)</sup>.

Systemic effects of secondary bile acids on host health have also been demonstrated by direct consumption or intrajejunal administering of specific secondary bile acids. For example, intake of UDCA given as granules, in healthy human subjects has been linked with improved postprandial blood glucose levels and raised GLP-1 secretion. This gut hormone controls glucose-induced insulin excretion and gastric emptying<sup>(43)</sup>. Furthermore, consumption of UDCA in rats has been shown to reduce fructose-induced metabolic syndrome, demonstrated by the addition of 150 mg/kg UDCA to drinking-water<sup>(44)</sup>. Moreover, in humans, intrajejunal taurocholic acid has been reported to decrease blood glucose and activate release of satiety hormones such as GLP-1 and peptide YY<sup>(45)</sup>.

Bile acids are thought to regulate various receptors influencing the regulation of metabolism and lipid profiles. Various secondary bile acids act as strong or weak agonists of FXR and TGR5, while some can suppress their activity, for example tauro- $\beta$ -muricholic acid, an FXR antagonist<sup>(46)</sup>. Therefore, the profile of circulating bile acid (BA) in contact with these receptors in different tissues may determine their level of regulation. Activation of such nuclear receptors may provide the key to linking the microbiota composition and activity with cardiovascular health via the bile acid converting activity of certain strains of gut bacteria. In light of this, circulating bile acids may represent useful biomarkers of cardiovascular health in humans.

**Table 1.** Circulating bile acids and their signalling potential

Bile acid	Mean fasting plasma concentration $\mu\text{M}$ ( $\pm$ SD) $n=80$	Hydrophobicity index (HI) <sup>(157)</sup>	Nuclear receptors agonist/antagonist
<b>Primary bile acids</b>			
Taurocholic acid	0.26 (0.45)	0.00	
Glycocholic acid	0.51 (0.52)	+0.07	
Taurochenodeoxycholic acid	0.22 (0.22)	+0.46	
Glycochenodeoxycholic acid	0.49 (0.35)	+0.51	
Chenodeoxycholic acid	0.89 (1.05)	+0.59	Mild TGR5 agonist <sup>(158)</sup> , potent FXR agonist <sup>(159)</sup> , PXR agonist <sup>(60)</sup>
Cholic acid	1.02 (1.83)	+0.13	FXR agonist <sup>(159)</sup> , TGR5 agonist <sup>(131)</sup>
<b>Secondary bile acids</b>			
Ursodeoxycholic acid	0.02 (0.03)	−0.31	
Lithocholic acid	0.02 (0.01)	−	Potent TGR5 agonist <sup>(158)</sup> , VDR agonist <sup>(160)</sup> , PXR agonist <sup>(161)</sup> , FXR agonist <sup>(159)</sup>
Deoxycholic acid	0.94 (0.66)	+0.72	TGR5 agonist <sup>(158)</sup> , FXR agonist <sup>(159)</sup> , PXR agonist <sup>(60)</sup> , Potent TGR5 agonist <sup>(162)</sup>
Taurolithocholic acid	0.00 (0.00)	+1.00	
Hyocholic acid	0.01 (0.01)	−	
Glycohyodeoxycholic acid	0.29 (0.30)	−0.26	LXR $\alpha$ agonist <sup>(163)</sup>
Tauro-ursodeoxycholic acid	0.02 (0.02)	−0.47	
Hyodeoxycholic acid	0.86 (0.60)	−	LXR $\alpha$ agonist <sup>(163)</sup>
Taurodeoxycholic acid	0.21 (0.26)	+0.59	TGR5 agonist <sup>(164)</sup>
Glycoursodeoxycholic acid	0.07 (0.06)	−0.43	
Glycolithocholic acid	0.54 (0.68)	+1.05	VDR agonist <sup>(160)</sup>
Glycodeoxycholic acid	0.23 (0.22)	+0.65	
Tauro- $\alpha$ muricholic acid	0.05 (0.04)	−0.84	FXR antagonist <sup>(131)</sup>
Taurohyocholic acid	0.02 (0.01)	−0.39	
Taurohyodeoxycholic acid	0.02 (0.02)	−0.31	Potent LXR $\alpha$ agonist <sup>(163)</sup>
Glycohyocholic acid	0.05 (0.04)	−0.40	
Tauro- $\beta$ -muricholic acid	0.00484 (0.00043) <sup>(165)</sup>	−0.78	FXR antagonist <sup>(46)</sup>

**Abbreviations:** FXR, farnesoid X receptor; LXR $\alpha$ , liver X receptor  $\alpha$ ; PXR, pregnane X receptor; TGR5, G-protein-coupled bile acid receptor 1; VDR, vitamin D receptor.

Adapted from circulating bile acid concentrations measured in fasting plasma using LC-MS/MS in healthy adults between the ages of 18 and 45 years <sup>(166)</sup>. Hydrophobicity index (HI) quantitatively defines the merged hydrophilic–hydrophobic balance of bile salts, based on bile salt capacity factor logarithms calculated using reversed-phase high-performance liquid chromatography (HPLC) and standardised arbitrarily to the indices of taurocholate (HI 0) and taurolithocholate (HI 1) <sup>(157)</sup>.

### The influence of prebiotics, probiotics and polyphenol-rich foods on bile acids, gut microbiota and CVD risk

An important contributor to the balance of the gut microbiota and, thus, bile acid homeostasis is diet. Gut bacteria profiles can be changed by dietary factors, with population studies demonstrating higher consumption of fruits, vegetables and fibres to have beneficial effects attributed to components such as probiotics, prebiotics and polyphenols <sup>(47–50)</sup>. Functional BSH enzymes have been found in all of the main species of gut bacteria with potential to modify primary bile acids, converting them to secondary bile acids <sup>(51)</sup>. Meanwhile very few species of gut bacteria have the BAI encoded enzymes required to perform bile acid 7 $\alpha$ -dehydroxylation and further bile acid transformation. Bacteria with BSH activity may also be involved in control of metabolic pathways such as those involved in glucose and lipid metabolism, integrity of the gut, inflammation and the circadian rhythm via generation of unconjugated bile acids from tauro-conjugated bile acids which allows further metabolism of bile acids by the gut microbiota <sup>(6)</sup>. This has been demonstrated with gastro-intestinal expression of BSH enzymes in mice, which resulted in changes in plasma bile acid profiles as well as altered transcription of lipid metabolism genes including peroxisome proliferator-activated receptor  $\gamma$ , angiopoietin-like 4, and ATP-binding cassette sub-family G member 5/8 (involved in cholesterol metabolism) in the liver or small intestine. Indeed, increased expression of BSH in these mice led to reduced weight gain and lower levels of plasma

cholesterol and liver triglycerides <sup>(6)</sup>. Therefore, any dietary component which has the ability to influence the proliferation of bacteria with BSH activity in the gut may also modulate bile acid homeostasis and the ability to impact on host cardiovascular health.

Fibres such as  $\beta$ -glucans, found in oats, and pectin, found in apples, and polyphenols such as proanthocyanidins, catechins or tannins, have been reported to possess bile acid sequestering activity <sup>(52,53)</sup>. This can cause the bile acids to travel unabsorbed into the colon where they are excreted or transformed again into secondary bile acids by the colonic bacteria. Studies have shown that pharmaceutical sequestering agents may decrease circulating LDL-C, reduce obesity, improve insulin sensitivity and induce thermogenesis <sup>(54)</sup>. Therefore, bile acid sequestering agents have potential for treatment of metabolic disease.

In view of the reported effects of prebiotics, probiotics and polyphenols on increasing the prevalence of gut bacteria with bile acid metabolising activity and bile acid sequestering activity, little is known about whether dietary modulation of circulating bile acids is associated with the beneficial effects reported on CVD risk markers. The latter part of this review will present the evidence from animal and human studies on the impact of prebiotics, probiotics and polyphenol-rich foods on bile acid metabolism as a potential mechanism for their positive effects on host lipid profiles and cardiovascular health. The studies presented have included measures of bile acids and modulation of the lipid profile and/or gut microbiota.



## Gut dysbiosis

A deviation from the natural balance in the gut microbiota (dysbiosis) is associated with obesity and conditions such as inflammatory bowel disease<sup>(55)</sup>. Reduced diversity and decreased levels of certain bacteria in the gut can lead to activation of the mucosal immune system, resulting in damage to the GI tract, which is particularly evident in inflammatory bowel disease<sup>(56)</sup>. Dysbiosis may also result in alterations in bile acid metabolism which can further disrupt gut homeostasis via effects on bacterial deconjugation, transformation and desulphation of bile acids<sup>(57)</sup>. This interruption of normal bile acid metabolism may result in increased intestinal epithelial inflammation and gut permeability, allowing translocation of bacterial lipopolysaccharides across the gut-blood barrier, which in turn results in systemic inflammation. A high-fat diet has been frequently associated with dysbiosis and bile acid dysregulation<sup>(58)</sup>. This reflects the importance of bile acids as postprandial signalling molecules that can affect gut mucosal defences via both antibacterial and anti-inflammatory actions reducing the synthesis of pro-inflammatory cytokines (TNF- $\alpha$ , monocytes and macrophages)<sup>(59)</sup>. In addition, decreased synthesis of secondary bile acids leads to reduced activation of nuclear receptors such as FXR, PXR, TGR5 and VDR. This can cause changes in bile acid synthesis and have a negative impact on lipid homeostasis<sup>(60)</sup>. Dysbiosis and the resulting interruption to the intestinal epithelial barrier is therefore linked with several diseases, including non-alcoholic fatty liver disease and cardiometabolic diseases<sup>(61)</sup>. Consumption of probiotics, prebiotics and polyphenol-rich foods may restore the balance of gut microbiota, regulating bile acid metabolism and restoring nuclear receptor activation.

## Probiotics

Probiotics are beneficial strains of bacteria with positive effects on host health. Both *Bifidobacterium* and *Lactobacillus* species have been identified as probiotics with BSH activity, with the highest BSH activity identified in *Bifidobacterium breve* and *Lactobacillus plantarum* LA3 strains<sup>(62)</sup>. BSH enzymes catalyse the first step in the conversion of conjugated primary bile acids into unconjugated species, allowing further transformation into secondary bile acid species, and may therefore lead to reduced reabsorption of bile acids in the enterohepatic cycle since secondary bile acids may be less easily absorbed. Certain secondary bile acids may be more readily excreted from the body, and bile acid neo-synthesis and LDL clearance may be enhanced<sup>(63,64)</sup>. LCA, for example, as the most hydrophobic bile acid, is reabsorbed poorly into the enterohepatic circulation, and thus, greater levels of LCA are excreted in the faeces<sup>(30)</sup>.

## Effects on lipid metabolism

Several studies using animal models have demonstrated reduced circulating LDL-C levels following probiotic supplementation<sup>(65–71)</sup>. Such results have also been replicated in human studies with the findings of a meta-analysis including 13 trials reporting a combined mean net change in total cholesterol (total participants  $n = 485$ ) of  $-1.66$  mM LDL-C as  $-1.27$  mM and TAG as

$-0.45$  mM<sup>(72)</sup> in those individuals treated with probiotics versus controls. Jones *et al.*<sup>(73)</sup> found that the consumption of *Lactobacillus reuteri* for 6 weeks reduced total and LDL-C by 8.9 % and 4.8 %, respectively, in healthy hypercholesterolaemic men and women. The treatment group ( $n = 56$ ) consumed 115 g of natural yoghurt and 10 g of microcapsules containing BSH-active *L. reuteri* (equivalent to  $1.4 \times 10^9$  CFU), twice per day, compared with a placebo group ( $n = 58$ ) given 125 g of natural yoghurt<sup>(73)</sup>. Similarly, Costabile *et al.*<sup>(63)</sup> observed a significant decrease in LDL-C (by 13.9 %) and a non-significant tendency for a reduction in total cholesterol (by 2 %) in healthy adults following 12 weeks of supplementation with *Lactobacillus plantarum* ( $2 \times 10^9$  CFU (0.1 g) twice daily) compared with a placebo (twice daily in the same capsular format)<sup>(63)</sup>. Meanwhile, Martoni *et al.*<sup>(74)</sup> found reduced serum LDL-C in hypercholesterolaemic adults ( $n = 10$ ), compared with baseline concentrations, after 4 weeks of consuming a delayed-release probiotic capsule (*Lactobacillus reuteri* NCIMB 30242,  $3-9 \times 10^9$  CFU twice daily)<sup>(74)</sup>.

## Effects on bile acids

Studies have been performed in animals and, to a lesser extent, in humans to provide further insights into the link between bile acid metabolism and lipid regulation in response to probiotic intake. A summary of studies which have investigated the effect of probiotic supplementation on bile acids in humans ( $n = 4$ ) and animal models ( $n = 16$ ) is presented in Table 2 and Supplementary Table 1, respectively. Several studies in animal models have found increased excretion of bile acids in stools following intervention with various probiotic bacteria strains<sup>(66,68,71,75–78)</sup>. However, in the limited number of human trials measuring faecal bile acid levels following chronic probiotic use, an effect on bile acid excretion has not been demonstrated<sup>(74,79)</sup>. Additionally, a study by Oshiro *et al.*<sup>(80)</sup> on premature infants born between 24 and 31 weeks of gestation, found that supplementing parenteral nutrition with *Bifidobacterium breve* resulted in reduced faecal total bile acids compared with a placebo<sup>(80)</sup>. These discrepancies highlight the need for further human studies examining the tentative link between probiotic bacteria and bile acid/absorption/excretion.

## Prebiotics

A dietary prebiotic is defined as 'a substrate that is selectively utilised by host microorganisms conferring a health benefit'<sup>(81)</sup>. The most common prebiotics are carbohydrate substrates, and the majority of studies associated with prebiotics and bile acid profiles or cholesterol homeostasis have been performed using  $\beta$ -glucans, fructans, fructose polysaccharide inulin oligosaccharides or galacto-oligosaccharides<sup>(82)</sup>. Dietary prebiotics can alter the microbiota profile in the gut in a dose-dependent manner, and recent evidence, from a limited number of studies, suggests this may impact upon CVD risk markers. For example, a recent review of 16S r-RNA studies on prebiotics and the microbiome found that, generally, consumption of inulin-type fructans ( $n = 17$  studies) in human studies resulted in increased



abundance of *Bifidobacterium* but had little effect on other gut microbes<sup>(83)</sup>. Meanwhile, supplementation with glucose-based fibres, such as types of resistant starch, had wider effects on the microbial community, especially abundance of *Ruminococcus* species. Galacto-oligosaccharides, xylo-oligosaccharides and arabinoxylan-oligosaccharides ( $n=8$  studies) generally led to increases in *Bifidobacteria* and only slight increases in relative abundance of other gut microbes<sup>(83)</sup>.

### Effects on lipid metabolism

Prebiotic consumption is thought to improve cardiovascular health via favourable effects on the blood lipid profile. A reduction in total cholesterol levels was demonstrated by Wang *et al.*<sup>(84)</sup> following chronic intake of barley  $\beta$ -glucan in  $n=30$  mildly hypercholesterolaemic adults (mean serum total cholesterol 5.49 mM). In this study, participants consumed breakfast with 3 g high-molecular-weight, 5 g low-molecular-weight or 3 g low-molecular-weight barley  $\beta$ -glucan (given as breakfast foods in the format of crepes, tortillas, porridge and chips formulated from barley to contain  $\beta$ -glucan varying in molecular weight) or a control diet (breakfast foods formulated from wheat and rice to substitute barley) for 5 weeks. They found that, while serum total cholesterol was reduced significantly, by 2.18%, after intake of 3 g high-molecular-weight barley  $\beta$ -glucans, cholesterol absorption and synthesis (both assessed using stable isotope methods) were unaffected<sup>(84)</sup>. Increased serum 7 $\alpha$ -hydroxy-4-cholesten-3-one concentrations, representing synthesis of bile acids, was noted in participants following consumption of the high-molecular-weight  $\beta$ -glucan. These results indicate that the cholesterol-lowering action of  $\beta$ -glucans may be related to enhanced bile acid synthesis, utilising circulating cholesterol, as opposed to inhibition of cholesterol synthesis or absorption. Another study by Nicolucci (2017) demonstrated a reduction in serum TAG in healthy, overweight children ( $n=22$ ) following supplementation with 8 g/d of oligofructose-enriched inulin for 16 weeks, compared with an isoeNERgetic dose of 3.3 g/d of maltodextrin placebo. The improvement in serum lipids coincided with increased faecal *Bifidobacterium* proliferation, many strains of which have strong BSH activity<sup>(85)</sup>. In a study by Cronin *et al.*<sup>(86)</sup>, daily calcium supplements (800 mg/d) consumed with short-chain fructo-oligosaccharides (3 g/d) for 24 months led to a time-by-treatment effect on the reduction in total and LDL-C levels in postmenopausal women ( $n=300$ ) compared with daily calcium (800 mg) alone<sup>(86)</sup>. The authors speculated that the reduced cholesterol absorption in the gut could be due to increased binding with the fructo-oligosaccharides, and potentially the bile acids, promoting their excretion in the stool.

### Effects on bile acids

As with probiotics, several studies ( $n=16$ ) have found a link between consumption of prebiotic foods and altered bile acid profiles or metabolism (Table 2 and Supplementary Table 1). For example, a number of studies in animal models have shown increased excretion of total bile acids in the faeces after chronic supplementation (between 4 and 17 weeks duration) with a prebiotic compared with a control intervention<sup>(87–90)</sup>. This has also

been demonstrated in two human studies<sup>(85,91)</sup>. In some cases, the enhanced excretion of bile acids could be related to increased proliferation of probiotic bacteria, including *Lactobacillus* and *Bifidobacterium* in the gut, possibly due to the BSH activity of such strains of bacteria. For example, Drzikova *et al.*<sup>(92)</sup> found, in addition to increased faecal total bile acids and reduced serum total cholesterol, an increase in gut proliferation of *Bifidobacterium* following consumption of 500 g oat-based extrudates, in the form of oat flour or oat bran, for 6 weeks in rats ( $n=10$ )<sup>(92)</sup>. Similarly, Meneses *et al.*<sup>(87)</sup> found increased gut *Lactobacillus* proliferation, as well as increased bile acid excretion, in mice ( $n=8$ ) after ingestion of *Ganoderma lucidum*, an oriental fungus with prebiotic properties, with a high-cholesterol diet<sup>(87)</sup>. This was also related to improved lipid profiles, with reduced serum total cholesterol (by 19.2–27.1%), LDL-C (by 4.5–35.1%) and TAG (by 16.3–46.6%) concentrations in the mice. A study by Gunness *et al.*<sup>(90)</sup> also found that a diet rich in oat  $\beta$ -glucans for 28 d reduced blood total bile acids, total and LDL-C compared with a control diet (no addition of  $\beta$ -glucan) in pigs ( $n=6$ )<sup>(90)</sup>. These findings were associated with increased faecal UDCA, changes in faecal HDCA and LCA (non-significant) and an overall reduction in faecal fatty acids, suggesting that  $\beta$ -glucans can alter bile acid metabolism. These results could provide, in part, the mechanism for the cholesterol-lowering effect of such foods since consumption of prebiotics can enhance proliferation of bacteria with bile acid metabolising activity in the gut.

In contrast, in a study by Wu *et al.*<sup>(167)</sup>, faecal secondary bile acids were reduced, while primary bile acids were increased in healthy adults ( $n=15$ ) after consumption of konjac (4.5 g/d), a high-molecular-weight, non-ionic, linear glucomannan consisting of  $\beta$ -1,4-linkages which resist digestion in the upper GI tract and is thus a rich source of soluble fibre. This was despite gut *Bifidobacterium* and *Lactobacillus* growth being increased, indicating a prebiotic effect, with enhanced proliferation of BSH bacteria strains. Although the effect on lipid profiles was not measured in this study, it may be that different mechanisms are involved in the cholesterol-lowering effect of some prebiotic foods, other than bile acid metabolising activity and subsequent reduced adsorption/increased neo-synthesis of bile acids. For example, it is known that konjac consumption can increase SCFA production in the gut and thus can modulate both BA profiles and SCFA concentrations<sup>(93)</sup>.

Some studies have also found addition of prebiotics to the diet to modulate circulating bile acid levels. For example, Hijova *et al.*<sup>(94)</sup> found reduced serum bile acids after a high-fat diet supplemented with 2% oligofructose-enriched inulin with extracts of horse chestnut (1%) and/or flaxseed (2%) in rats ( $n=12$ ), compared with a high-fat diet alone. For rats treated with inulin alone, this was also linked with reduced total cholesterol and TAG concentrations, as well as increased Lactobacilli in the stools<sup>(94)</sup>. However, a study by Lærke *et al.*<sup>(95)</sup> found no effect of rye wholemeal and rye bran on circulating bile acids in hypercholesterolaemic pigs ( $n=8$ ) despite reduced plasma total-to-LDL-C ratio<sup>(95)</sup>. Although faecal bile acid excretion was not measured, it is also possible that the effect observed is dependent on both the type of prebiotic consumed and the animal species used. For example, pig models have a closer similarity to human lipid metabolism compared with rat models. In



**Table 2.** Summary of studies investigating the effect of polyphenols, prebiotics and probiotics on bile acids and lipid profiles/gut microbiota in humans

Author	Number (n) – study duration/ design	Diet/daily dose	Results		
			Bile acids	Lipid profiles	Gut microbiota
<b>Probiotics</b>					
(80)	n = 18 (Group I), n = 17 (Group II), Infants born between 24 and 31 weeks of gestation, BW < 1 500 g DB, RCT 8 weeks	<b>Group I:</b> parenteral nutrition (PN), with glucose (8 %; glucose infusion rate: 3–4 mg/kg/d), amino acids (1.0–1.5 g/kg/d), and fatty acids (Intralipos; high content of n-6: ~0.5–1.0 g/kg/d) + mother's colostrum as a trophic feeding + mother's breast milk fortified with HMS-1 (Morinaga, Tokyo, Japan) and medium-chain TAG oil with placebo supplementation once daily <b>Group II:</b> parenteral nutrition (PN), with glucose (8 %; glucose infusion rate: 3–4 mg/kg/d), amino acids (1.0–1.5 g/kg/d), and fatty acids (Intralipos; high content of n-6: ~0.5–1.0 g/kg/d) + mother's colostrum as a trophic feeding + mother's breast milk fortified with HMS-1 (Morinaga, Tokyo, Japan) and medium-chain TAG oil with <i>Bifidobacterium breve</i> supplementation (2.5 × 10 <sup>8</sup> ) CFU once daily	<b>Group II:</b> ↓ total faecal BAs	<b>Group I:</b>	<b>Group I:</b> ↑ faecal bacterial counts, including <i>Bifidobacterium</i> , ↑total faecal organic acids; total faecal SCFAs and plasma n-3 fatty acids
(79)	n = 16 (Group I), healthy n = 15 (Group II), adults with MS (identified from outpatient clinic) n = 13 (Group III), adults with MS RCPI 12 weeks	<b>Group I:</b> usual diet, no intervention <b>Group II:</b> MS patients following usual diet, no intervention  <b>Group III:</b> MS patients following usual diet with (3 bottles a day, 65 ml, containing <i>Lactobacillus casei</i> Shirota at a concentration of 10 <sup>8</sup> /ml)	<b>Group I versus Group II:</b> ↑stool total bile acids, proportions of primary, secondary, taurine- or glycine-conjugated bile acids  <b>Group II versus Group III:</b> ↔ proportions of primary, secondary, taurine- or glycine-conjugated bile acids	<b>N/A</b>	<b>Group I versus Group II:</b> ↓Bacteroidetes-to-Firmicutes ratio, no change in <i>Bacteroides</i> and <i>Prevotella</i> <b>Group II versus Group III:</b> no change in gut microbiota
(74)	n = 5 (Group I), HyperChol  n = 5 (Group II), HyperChol n = 4 (Group III), healthy RCPI  4 weeks followed by 2-week post-intervention period	<b>Group I:</b> usual diet with standard-release probiotic capsule ( <i>Lactobacillus reuteri</i> NCIMB 30242). During week 1, subjects received 3.0 × 10 <sup>9</sup> CFU <i>L. reuteri</i> once daily; during weeks 2, 3 and 4, subjects received 3.0 × 10 <sup>9</sup> CFU, 6.0 × 10 <sup>9</sup> CFU and 9.0 × 10 <sup>9</sup> CFU respectively, twice daily with lunch and dinner <b>Group II:</b> usual diet with delayed-release probiotic capsule ( <i>Lactobacillus reuteri</i> NCIMB 30242) dosing schedule same as Group I <b>Group III:</b> usual diet with delayed-release probiotic capsule ( <i>Lactobacillus reuteri</i> NCIMB 30242 (6.0 × 10 <sup>9</sup> CFU)) twice daily with lunch and dinner	<b>Group I:</b> ↑plasma mean total BA, conjugated and unconjugated BA post 1 week <b>Group II versus baseline:</b> ↔ plasma mean total BA, conjugated and unconjugated BA <b>Group III:</b> ↑plasma total BA, conjugated and unconjugated BA	<b>Group I:</b> ↓LDL-C (ns) and total plant sterol  <b>Group II:</b> ↓LDL-C, ↑total plant sterols  <b>Group III:</b> no change in total plant sterols	<b>Group I:</b> no change in faecal microbiome <b>Group II:</b> no change in faecal microbiome

Table 2. (Continued)

Author	Number (n) – study duration/ design	Diet/daily dose	Results		
			Bile acids	Lipid profiles	Gut microbiota
<b>Prebiotics</b>					
(85)	n = 22 (Group I) n = 20 (Group II) Healthy children, 7–12 years old, OW or O (>85th percentile of BMI) DB, PCT 16 weeks	<b>Group I:</b> usual diet with 8 g/d (55.2KJ AU/d) of oligofructose-enriched inulin <b>Group II:</b> Usual diet with isoenergetic dose of 3.3 g/d of maltodextrin placebo dissolved in water	<b>Group I:</b> ↔ BAs from baseline <b>Group II:</b> ↑primary BAs	<b>Group I:</b> ↓serum triglycerides	<b>Group I:</b> ↑in faecal <i>Bifidobacterium</i> , ↓ in faecal <i>Bacteroides vulgatus</i>
(167)	n = 15 per group (2 groups) Healthy DB, PCT 4 weeks	<b>Group I:</b> 7-d cycle menus of a typical low-fibre Taiwanese diet (diet provided energy and typical nutrient pattern of the adult population in Taiwan) supplemented with konjac (4.5 g/d) <b>Group II:</b> 7-d cycle menus of a typical low-fibre Taiwanese diet (diet provided energy and typical nutrient pattern of the adult population in Taiwan) supplemented with placebo (maize starch, 4.5 g/d)	<b>Group I:</b> ↓faecal secondary BAs, ↑faecal primary BAs	<b>N/A</b>	<b>Group I:</b> ↑faecal Bifidobacteria and Lactobacilli levels
(168)	n = 16 Healthy CO 12 weeks (2-week pre-treatment phase, 8-week treatment phase and 2-week post-treatment phase)	Free choice of diet and during the 8-week treatment phase with 3.5 g of ispaghula husk (in the form of one sachet of Fybogel Orange) mixed in 150 ml of cold water, twice a day after breakfast and after the evening meal	Treatment ↓faecal lithocholic and isolithocholic acids, ↓ratio of lithocholic acids to deoxycholic acid, bile acid parameters returned to initial values subsequent to treatment	<b>N/A</b>	<b>N/A</b>
(91)	n = 9 Adults with history of proctocolectomy for ulcerative colitis (n = 7) or Crohn's disease (n = 2) Short-term interventional CO 3 d treatment, 4 d washout, 3 d treatment	<b>Treatment I:</b> basal menu composed of common food items with 75 g of breakfast cereals based on extruded oat bran concentrate with native β-glucans <b>Treatment II:</b> basal menu composed of common food items with 75 g of breakfast cereals based on extruded oat bran concentrate with hydrolysed β-glucans	<b>Treatment I versus Treatment II:</b> ↑median excretion of BAs	<b>Treatment I versus Treatment II:</b> TC excretion remained unchanged, ↓TC absorption, ↑serum lathosterol concentration (reflecting cholesterol synthesis)	<b>N/A</b>
<b>Polyphenol-rich foods/extracts</b>					
(113)	n = 40 (23W/17M), HyperChol RCT, CO 8-week treatment with 4-week washout	<b>Treatment I:</b> 2 apples per day (Renetta Canada, rich in PAs) <b>Treatment II:</b> sugar- and energy-matched apple control beverage	<b>Treatment I:</b> similar changes in BAs but exploratory analysis confirmed link between TC and circulating LCA and GUDCA, ↑LCA associated with ↑TC and TC↓ as GUDCA↑ in females only	<b>Treatment I:</b> ↓serum TC, LDL-C and TAG	<b>N/A</b>
(169)	n = 12 (5 F/7 M) HyperChol RCT, DB, CO 3-week treatments with 2-week washouts	<b>Treatment I:</b> VOO naturally containing 80 mg phenolic compounds (PC)/kg <b>Treatment II:</b> PC-enriched VOO containing 500 mg PC/kg, from olive oil	<b>Treatment III:</b> ↓relative proportion of isolithocholic acid (referred to the total of faecal BAs) versus pre-treatment	<b>Treatment III:</b> ↓serum ox-LDL concentrations	<b>Treatment III:</b> ↑numbers of <i>Bifidobacterium</i> versus Treatment I

Table 2. (Continued)

Author	Number (n) – study duration/ design	Diet/daily dose	Results		
			Bile acids	Lipid profiles	Gut microbiota
(133)	n = 16 (6 M/10 F) Healthy CO trial, 6-week (3 cycles of 2 weeks each)	<b>Treatment III:</b> PC-enriched VOO containing a mixture of 500 mg PC/kg from olive oil and thyme, 1:1 <b>Treatment I:</b> 84 g/d of sun-dried raisins (SDR) <b>Treatment II:</b> 126 g/d of SDR <b>Treatment III:</b> 168 g/d of SDR	<b>Treatment I:</b> ↓ in faecal BAs from baseline, remained low with Treatments II/III Major ↓ in faecal lithocholic, deoxycholic, chenodeoxycholic and cholic acids, concentrations remained low with Treatments II/III	N/A	N/A
(135)	n = 13 Healthy RCT, DB, CO 21 d treatment, 4-week washout	<b>Treatment I:</b> NCEP Step 1 diet with black tea prepared as powder <b>Treatment II:</b> National Cholesterol Education Program Step I type diet with placebo prepared as powder	<b>Treatment I/II:</b> ↔ on levels and proportions of faecal BAs	N/A	<b>Treatment I/II:</b> no effect on bacterial profile
(114)	n = 47 Borderline HyperChol RGC, DB 3 months	<b>Group I:</b> black tea extract (BTE) tablets (250 mg) containing 166.5 mg BTE (66.6 %) <b>Group II:</b> placebo tablets containing dextrin (66.6 %) Usual diet maintained throughout	<b>Group I/II:</b> ↔ in key Bas	<b>Group I:</b> ↓ TC and LDL-C, ↓ TAG levels	N/A

**Abbreviations:** BA, bile acid; BSH, bile salt hydrolysing; BW, body weight; CO, crossover; DB, double blind; HDL-C, high-density lipoprotein cholesterol; HyperChol, hypercholesterolaemic; LDL-C, low-density lipoprotein cholesterol; MS, metabolic syndrome; O, obese; OW, overweight; PCT, placebo control trial; RCPI, randomised controlled prospective intervention; RCT, randomised control trial; RGC, randomised group comparison; SCFA, short-chain fatty acid; TC, total cholesterol; TAG, triacylglycerol; VOO, virgin olive oil.

addition, certain prebiotics, especially inulin-type fructans, may have a positive effect on endothelial function via effects on the gut microbiota, bile acid profiles and activation of the nitric oxide (NO) synthase/NO pathway responsible for NO-dependent endothelium relaxation. Inulin-type fructans promote proliferation of *Bifidobacterium*, which contribute to NO generation by reducing pH and acidic non-enzymatic reduction of nitrite <sup>(96)</sup>. Catry *et al.* <sup>(97)</sup> demonstrated a positive effect of inulin-type fructans on endothelial dysfunction, an important marker of CVD, in mice <sup>(97)</sup>. Apoe<sup>-/-</sup> mice were fed an n-3 polyunsaturated fatty acid (PUFA)-depleted diet (12 weeks) with or without inulin-type fructans supplementation (for last 15 d of the study). Endothelial dysfunction was completely reversed in the mesenteric and carotid arteries, through activation of the NO synthase/NO pathway. In addition, inulin-type fructan supplementation led to increased proliferation of NO-producing bacteria and *Akkermansia*, with reduced abundance in bacteria which are implicated in synthesis of secondary bile acids. The observed changes in bile acid composition, along with increased L-cell density and enhanced GLP-1 production, were proposed as being responsible for activation of the NO synthase/NO pathway and ultimately for preservation of endothelial function.

Although some potential mechanisms for beneficial effects of prebiotics on CVD risk have been derived from the animal studies presented above, the lack of studies conducted in humans which have included measures of gut microbiota composition and markers of bile acid metabolism warrants further study, as the links between bile acid and lipid regulation remain inconclusive.

### Polyphenol-rich foods

Diets high in phenolic compounds such as fruits and vegetables are considered to have beneficial effects on gut health. In addition to fibre, polyphenols have also been reported to reach the gut intact where they are fermented by the resident bacteria leading to generation of smaller phenolic compounds which can be absorbed in the colon <sup>(98)</sup>. For example, procyanidins are metabolised by the gut bacteria into several metabolites such as phenyl valerolactone and phenylacetic and phenylpropionic acids which are more easily absorbed and capable of producing systemic effects including anti-inflammatory and vasodilatory effects <sup>(99,100)</sup>.

The prebiotic effect of apples, specifically the high-polyphenol-containing Renetta Canada variety, was highlighted by a study conducted by Koutsos *et al.* <sup>(101)</sup>. Using a batch culture colonic model inoculated with faeces from healthy human donors ( $n = 3$ ), the apples induced substantial changes in the composition and metabolic activity of the gut microbiota *in vitro*, with a reduction in abundance of Bacteroidetes, and enhanced proliferation of *Proteobacteria*, *Bifidobacteria* and *Faecalibacterium prausnitzii*, found relative to inulin and cellulose control models <sup>(101)</sup>. Sembries *et al.* <sup>(102)</sup> also showed increased faecal Lactobacilli and *Bifidobacterium* following addition of apple pomace (the dried solid by-product of apple product manufacturing) to the diet of rats ( $n = 12$ ) for 4 weeks <sup>(102)</sup>. However, apples and apple pomace contain other active components which could have affected the gut

microbiota such as fibre in the form of pectin. Prebiotic effects have also been shown for red wine, known to be high in polyphenols, in humans ( $n = 20$ ) <sup>(103)</sup>. Consumption of red wine (272 ml/d) enhanced the growth of *Blautia coccoides*–*Eubacterium rectale* groups, *Bifidobacterium*, *Eggerthella lenta* and *Bacteroides uniformis*, while growth of *Clostridium* and *Clostridium histolyticum* was inhibited after 20 d compared with consumption of an alcohol control (100 ml/d gin). However, such beneficial effects on composition of the gut microbiota were not found in a recent study by Wallace *et al.* <sup>(104)</sup>. Indeed, ingestion of a high-polyphenol boysenberry beverage (750 mg polyphenols) did not give rise to any significant changes in faecal bacteria, including total Lactobacilli, *Bifidobacterium* and *Bacteroides* or *Clostridium perfringens* in healthy human volunteers ( $n = 25$ ) <sup>(104)</sup>. The discrepancies between different studies may be due to different polyphenol doses, the selected comparator intervention, types of food given and the polyphenolic compounds they contain, with an effect in particular of the food matrix.

### Effects on lipid metabolism

Polyphenols, particularly complex polyphenols, such as proanthocyanidins, have been found to influence the enterohepatic circulation via sequestering of bile acids within the colon and/or increasing the proliferation of gut microbiota involved in the de-conjugation and hydrolysis of primary to secondary bile acids <sup>(105–108)</sup>. For example, supplementation with green tea polyphenols (3.2 g epigallocatechin gallate (EGCG) per kg of high-fat chow) was found to increase faecal bile acid concentrations by 1.5-fold in mice ( $n = 20$ ), from approximately 0.4  $\mu\text{mol/d}$  to 1.1  $\mu\text{mol/d}$  <sup>(109)</sup>. This likely occurs owing to inhibition of bile acid micelles because of hydrophobic interactions with polyphenolic compounds such as EGCG. This phenomenon has been demonstrated in *in vitro* studies to lead to the elimination of phosphatidylcholine and cholesterol from the micellar structure, which results in reduced bile acid solubility <sup>(110)</sup>. Bile acid binding assays have revealed that, in *in vitro* mixtures, 30 % of taurocholic acid, 70 % of glycodeoxycholic acid and 25 % of taurodeoxycholic acid could be bound by grape seed extract (containing 50.8 g total flavanols per 100 g of extract) and similarly by the polyphenols gallic acid, catechin and epicatechin <sup>(111,112)</sup>. Further studies, particularly in humans, would be valuable to fully understand the impact of increased polyphenol intakes on bile acid sequestering action.

Indeed, consumption of polyphenols has been shown to improve dyslipidaemia in several human studies. Koutsos *et al.* <sup>(113)</sup> found a beneficial effect of consuming two high-polyphenol Renetta Canada apples daily (total polyphenols, 239 mg/d) for 8 weeks on lipid profiles, with reduced serum total and LDL-C and TAG concentrations in slightly hypercholesterolaemic subjects ( $n = 40$ ) <sup>(113)</sup>. The changes in serum lipids were also associated with small but significant improvements in endothelium-dependent microvascular vasodilation, a marker of endothelial function and another indicator of cardiovascular health. No significant changes in circulating bile acids were found, but further exploratory analysis demonstrated links between circulating LCA and glycodeoxycholic acid (GUDCA) and the total cholesterol response in women. Fujita





and Yamagami (2008) found a similar response to black tea polyphenols, with improved circulating total and LDL-C and TAG levels following 3 months of supplementation with 166.5 mg black tea extract (taken in tablet form) ( $n = 47$ )<sup>(114)</sup>. Furthermore, Tzounis *et al.*<sup>(170)</sup> also demonstrated significant reductions in plasma TAG concentrations in healthy human volunteers ( $n = 22$ ) following ingestion of a high-cocoa-flavanol drink (494 mg cocoa flavanols/d) for a 4-week period, compared with a low-cocoa-flavanol drink (23 mg cocoa flavanols/day). This occurred concurrently with significantly increased *Bifidobacterium* and *Lactobacilli* populations, as well as significantly reduced *Clostridia* counts in the gut, demonstrating the potential link between polyphenol-induced alterations in gut microbiota and improved CVD risk markers.

Beneficial effects of polyphenols on CVD risk are not limited to improved lipid profiles. In rat models of CVD, the polyphenol resveratrol (0.4 % administered in a standard chow diet) was shown to lower production of trimethylamine-*N*-oxide. This amine oxide is generated from choline, betaine and carnitine by gut microbial metabolism of red meat and fat<sup>(48)</sup> and is linked with an increased risk for significant adverse cardiovascular events<sup>(115)</sup>. Trimethylamine-*N*-oxide encourages development of atherosclerosis (narrowing of arteries caused by fatty plaques, leading to CVD), and plays a role in cholesterol uptake and BA synthesis, reducing reverse cholesterol transport and downregulating hepatic CYP7A1 activity<sup>(116,117)</sup>. Indeed, in the same rat model, a reduction in vascular disease was observed<sup>(48)</sup>. The findings observed were shown to correlate with the increased production of new bile acids due to changes in the enterohepatic FXR-FGF15 pathway after modulation of the gut microbiota. Resveratrol was found to significantly increase expression of CYP7A1, leading to increased BA synthesis in the liver while also enhancing the growth of *Lactobacillus* and *Bifidobacterium* in the gut<sup>(48)</sup>. It was suggested, therefore, that consumption of this polyphenol can limit the effects of trimethylamine-*N*-oxide on CVD development by promoting greater uptake of circulating cholesterol by the liver to make new bile acids.

### Effects on bile acids

Evidence from the animal studies may provide an explanation for the potential mechanisms of action behind polyphenol-induced improvements in lipid risk markers, since these beneficial effects are linked to changes in circulating and excreted bile acids. A summary of studies conducted in humans and animals is presented in Table 1 and Supplementary Table 1 (see supplementary material), respectively. Aprikian *et al.*<sup>(118)</sup> found that the daily consumption of apples decreased plasma total and LDL-C (by 22 % and 70 %, respectively) concentrations in rats, which were associated with increased faecal excretion of total bile acids (+56 % in lean and +30 % in obese rats)<sup>(118)</sup>. A recent study by Ravn-Haren *et al.*<sup>(119)</sup> also demonstrated a beneficial effect of apple pomace on total cholesterol levels in mice ( $n = 40$ ), with an associated increase in excreted total and primary bile acids after 4 weeks of consumption<sup>(119)</sup>. In another study, similar results were shown following supplementation with the green tea polyphenol, EGCG, with reduced serum cholesterol concentrations and severity of fatty

liver disease and increased faecal excretion of cholesterol and total lipids in mice ( $n = 50$ ). Reduced intestinal and increased faecal excretion of total bile acids was also found, indicating an effect on bile acid reabsorption and neo-synthesis as a potential mechanism for the observed reduction in cholesterol levels<sup>(109)</sup>. A pattern of increased faecal bile acids, with reduced serum total and LDL-C and TAG concentrations, has been shown in multiple studies in animal models, using a range of polyphenols (EGCG, kaempferol, anthocyanins, flavonoid extracts, quercetin and resveratrol) and high-polyphenol-containing foods (pu-erh tea, cassini herbal tea and red yeast rice)<sup>(120–128)</sup>. Conversely, one study by Zhang *et al.*<sup>(129)</sup> found no change in TAG or total cholesterol levels, but increased LDL-C, despite increased faecal total bile acid excretion and up-regulation of hepatic CYP7A1 following administration of quercetin (0.4 %) in rats ( $n = 20$ )<sup>(129)</sup>. These reported inconsistencies may be due to other studies investigating the effect of quercetin on hypercholesterolemic animals or those fed a high-cholesterol diet, while Zhang *et al.* used healthy rodents with a standard diet formulation (AIN-93G diet)<sup>(121,129,130)</sup>.

A study by Guo *et al.*<sup>(131)</sup> found that treatment with phenolic blueberry extract (5 g per litre of drinking-water daily, 14 weeks) led to improved markers of metabolic disease in mice ( $n = 9$ ), in conjunction with enhanced brown adipose tissue energy expenditure and improved hepatic lipid metabolism through TGR5 and FXR activation<sup>(131)</sup>. Notably, the phenolic extract led to increased proliferation of *Akkermansia*, *Bifidobacterium*, *Lactobacillus* and *Desulfovibrio* in the gut, which correlated with increased plasma secondary bile acids such as chenodeoxycholic acid, DCA and LCA and reduced circulating tauro-( $\alpha$ )-muricholic acid (T $\alpha$ MCA) and tauro-( $\beta$ )-muricholic acid (T $\beta$ MCA), both of which are potent FXR inhibitors<sup>(131)</sup>. Similarly, a study by Anhe *et al.*<sup>(132)</sup> showed treatment of mice ( $n = 12$ ) with polyphenol-rich extract of camu camu (an Amazonian fruit, daily oral doses (200 mg/kg) of re-suspended crude extract for 8 weeks), led to improved metabolic health with improved glucose tolerance, reduced weight gain and adiposity and blunted metabolic inflammation and endotoxaemia<sup>(132)</sup>. This was linked to enhanced brown adipose tissue energy expenditure and strongly correlated with increased expression of TGR5 in brown adipocytes<sup>(132)</sup>. In addition, the extract led to altered plasma bile acid profiles, with reduced circulating T $\alpha$ MCA and T $\beta$ MCA and increased proportion of  $\beta$ -muricholic acid,  $\omega$ -muricholic acid, chenodeoxycholic acid, DCA and UDCA as well as decreased circulating bile acids and increased proportion of secondary and of unconjugated bile acids. This was coupled with a significant increase in gut *Akkermansia muciniphila* and a reduction in *Lactobacillus*. These results indicate that activation of nuclear receptors, TGR5 and FXR play a key role in reduced metabolic disease risk from consumption of phenolic compounds and related to microbial metabolism of bile acids, resulting in alterations in the bile acid pool with reduced FXR antagonists (such as T $\alpha$ MCA and T $\beta$ MCA) and increased FXR/TGR5 agonists (such as cholic acid).

However, most of the above studies only quantified total bile acids and did not measure bile acid profiles and were conducted in animal models. Thus, further mechanistic studies investigating polyphenol consumption, microbiota modulation and changes in circulating bile acid profiles in humans are warranted.

The effect of phenolic compounds on bile acids may be specific to the type of polyphenol and the matrix in which it is given. In humans, consumption of sun-dried raisins for 6 weeks resulted in reduced faecal bile acids compared with baseline levels, especially for lithocholic, deoxycholic, chenodeoxycholic and cholic acids<sup>(133)</sup>. It is worth noting that, while raisins are high in phenolic compounds (total phenolic content approximately 9–12 mg of gallic acid equivalents per gram), they also contain high levels of fibre, which could play a role in altering bile acid profiles either physically by binding of bile acids and inhibiting their resorption or via effects on the gut microbiota<sup>(134)</sup>. Furthermore, black tea polyphenols, given as a powder or in tablet form, have been shown to have no effect on excreted bile acids in humans, despite their beneficial effect on lipid profiles<sup>(114,135)</sup>. Future studies could be useful to further investigate links between changes in bile acids and improvements in CVD risk markers following polyphenol consumption.

### Potential mechanisms of action

The studies highlighted above indicate that a number of potential mechanisms may exist by which dietary components that promote beneficial changes on gut microbiota composition impact on lipid regulation (Fig. 3).

#### BSH activity

In addition to effects on absorption of bile acids, via bile acid metabolising action initiated by BSH activity, the ability of pre/probiotics and polyphenol-rich foods to either stimulate or inhibit FXR may also affect their ability to impact upon host metabolism. In a study by Degirolamo *et al.*<sup>(78)</sup>, the probiotic mixture VSL#3 (containing BSH active probiotic strains) had a significant effect on bile acid profiles in mice after oral gavage with  $50 \times 10^9$  CFU/d for 21 d, compared with daily oral gavage with saline for the same duration<sup>(78)</sup>. The high levels of BSH activity inhibited the enterohepatic FXR response and led to increased excretion of total bile acids in the faeces with no effect on the faecal CA/DCA ratio but a reduced ratio of faecal conjugated:unconjugated bile acids. In addition, a reduction in gut FGF15 expression and increased bile acid synthesis in the liver was shown; however, serum lipids were not measured. FGF15 is the mouse homologue of FGF19 (released upon activation of FXR) which migrates to the liver to activate the cellular receptor FGFR4, inhibiting CYP7A1 expression<sup>(136)</sup>. Conversely, Choi *et al.*<sup>(171)</sup> found increased FXR expression in mice following a high-fat diet supplemented with *L. curvatus* and *L. plantarum* ( $n = 10$ ) for 6 weeks. This was coupled with changes in metabolic markers such as reduced plasma TAG. Similarly, in humans, FGF19 expression may be increased in response to gut proliferation with probiotic bacteria. For example, in addition to effects on LDL-C concentrations, Martoni *et al.*<sup>(74)</sup> found that *Lactobacillus reuteri* supplementation led to stimulation of the FXR axis as well as increased levels of circulating bile acids. As such, in addition to further *in vivo* studies on probiotics and bile acid excretion, studies on the effect of probiotics and food components, which lead to increased proliferation of probiotic bacteria in the gut, on FXR activity would also be of interest.

### Bile acid sequestrants


Another mechanism to explain the increased excretion of bile acids following consumption of prebiotics and polyphenol-rich foods could be due to the bile sequestering capacity of these dietary components (Fig. 3). Dietary fibre such as  $\beta$ -glucans and polyphenol compounds can bind to bile acids in the intestine to drive the bile acids down to the colon, which modifies their absorption and excretion<sup>(137)</sup>. This leads to a reduction in hepatic bile acid concentration and, in turn, activates CYP7A1, the enzyme responsible for conversion of cholesterol to bile acids<sup>(138)</sup>. A number of studies have noted increased hepatic CYP7A1 expression, indicating bile acid neo-synthesis following consumption of polyphenolic compounds in animals<sup>(139,140)</sup>. In rodents, increased CYP7A1 expression has been shown in conjunction with reduced serum total cholesterol and TAG following administration of grape seed polyphenols<sup>(141,142)</sup>. In line with these findings, Downing *et al.*<sup>(143)</sup> showed elevated faecal bile acids and reduced serum bile acids following administration of grape seed polyphenols in rats ( $n = 8$ )<sup>(143)</sup>. In addition, the grape seed polyphenols resulted in reduced serum TAG levels and increased faecal excretion of cholesterol and total lipids. However, serum total cholesterol was not affected in this study. Quifer *et al.*<sup>(144)</sup> also found increased faecal excretion of cholesterol, as well as increased excretion of secondary bile acids deoxycholic and lithocholic acid, following grape seed extract (GSE) consumption in pigs ( $n = 6$ )<sup>(144)</sup>.

Evidence for increased CYP7A1 expression in the liver has also been demonstrated in animal models with consumption of prebiotics. Mandimika *et al.*<sup>(89)</sup> found increased hepatic CYP7A1 expression and improved circulating lipid profiles after consumption of broccoli fibre (75 g/kg daily) in rats ( $n = 16$ ) fed a high-corn-oil diet for 17 weeks. However, Lærke *et al.*<sup>(95)</sup> found that consumption of rye wholemeal and rye bran led to inhibition of CYP7A1 expression in hypercholesterolaemic pigs ( $n = 8$ ) along with reduced plasma TC/LDL-C; therefore, the effect may be specific to type of prebiotic given and animal model used<sup>(95)</sup>.

Chronic supplementation with probiotics may also lead to increased hepatic CYP7A1. For example, a study by Jeun *et al.*<sup>(71)</sup> found a greater CYP7A1 expression, coupled with increased bile acid excretion and improved lipid profiles, following supplementation with *L. plantarum* ( $10^9$  CFU) in mice ( $n = 7$ ) for 4 weeks<sup>(71)</sup>. Similarly, Michael *et al.*<sup>(76)</sup> showed the same effects on CYP7A1 expression, bile acid excretion and improved blood lipids, following 14 d of consumption of *L. plantarum* ( $10^8$  CFU/d) in mice ( $n = 12$ )<sup>(76)</sup>. The effect on CYP7A1 expression and lipid profiles was revealed by Wang *et al.*<sup>(145)</sup>, while Zhai *et al.*<sup>(75)</sup> also found a similar effect on bile acid excretion but did not include measurement of lipid parameters<sup>(75,145)</sup>. These results demonstrate a beneficial effect of *L. plantarum* on CVD risk markers, which may be in part mediated by increased bile acid neo-synthesis.

### Expression of lipid synthesis genes

In addition, fermentation of soluble fibres by the gut bacteria results in the production of SCFA which are easily absorbed into the portal vein and can then be metabolised in the liver. There is some evidence that SCFA, particularly propionic acid, are



**Fig. 3.** Potential mechanisms to explain the beneficial effects of prebiotics, probiotics and polyphenol-rich foods on bile acid metabolism and lipid regulation: BSH strains of probiotic bacteria in the gut can modify primary bile acids to produce secondary bile acids which are less well absorbed in the enterohepatic cycle. These bacteria also produce SCFAs, via fermentation of fibre, acetate, which enhances hepatic cholesterol synthesis, and propionate, which may inhibit cholesterol synthesis and encourage uptake of circulating cholesterol via up-regulation of hepatic LDL-receptors. Fibre and polyphenol-rich foods may act as bile sequestering agents, enhancing excretion of bile acids and encouraging bile acid neo-synthesis to replace those lost in the faeces.

involved in suppression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme for cholesterol synthesis in the liver, leading to up-regulation of LDL receptors (Fig. 3) <sup>(146)</sup>. For example, Meneses *et al.* <sup>(87)</sup> showed that a high-cholesterol diet supplemented with extract of *Ganoderma lucidum* (0.5–1.0 %) for 43 d in C57BL/6 mice ( $n = 8$ ) led to reduced expression of HMGR coupled with an increase in LDL-receptor gene expression in the liver <sup>(87)</sup>. These changes in gene expression coincided with reduced serum total and LDL-C, TAG levels, and hepatic total cholesterol and TAG content. Supplementation with probiotic bacteria, *Enterococcus faecium* ( $5.0 \times 10^9$  CFU/ml in PBS, 1 ml/d) for 35 d has also been shown to inhibit expression of hepatic HMGR, while increasing LDL-receptor and CYP7A1 expression in mice ( $n = 5$ ), with resulting improvements in serum lipid profiles <sup>(67)</sup>. Similar effects have been demonstrated for polyphenol extracts with reduced HMGR expression after consumption of a flavonoid- and saponin-rich extract (0.25–0.5 %) with a high-cholesterol diet for 35 d in mice ( $n = 8$ ) <sup>(120)</sup>. These changes were in parallel to the increased faecal bile acid secretion and bile acid neo-synthesis (increased CYP7A1 in the liver) observed, as well as beneficial effects on circulating lipid profiles. Conversely, several studies have shown that consumption of probiotics, prebiotics or polyphenol-rich foods may result in up-regulation of hepatic HMGR expression. For example, Damodharan *et al.* <sup>(77)</sup> found increased HMGR expression in mice ( $n = 8$ ), following ingestion of *L. acidophilus* ( $3 \times 10^8$  CFU/ml) with a high-cholesterol diet for 32 d <sup>(77)</sup>. This was despite an increase in hepatic LDL-receptor expression and reduced serum LDL-C. A study by Parnell *et al.* <sup>(156)</sup> also showed increased hepatic HMGR as a result of oligofructose and inulin supplementation (10–20 %) for 10 weeks in rats ( $n = 8$ ). Indeed, Mandimika *et al.* <sup>(89)</sup> demonstrated increased

hepatic HMGR expression in rats ( $n = 16$ ) when fed broccoli fibre (75g/kg daily) as part of a high-corn-oil diet for 17 weeks <sup>(89)</sup>. This was despite improvements in circulating lipid profiles and increased excretion of bile acids. In addition, Mueller *et al.* <sup>(147)</sup> found an association between increased serum propionate and raised LDL-C in humans ( $n = 163$ ) using linear regression models to examine the relationship between changes in SCFAs with cardio-metabolic parameters following introduction of different diets (carbohydrate-rich, protein-rich and unsaturated-fat-rich) for 6 weeks <sup>(147)</sup>. These contrasting findings could reflect the differences in lipid metabolism pathways which exist between rats and humans. Further studies are needed to fully elucidate the role of SCFAs in regulating cholesterol synthesis in humans.

There is limited evidence that the different SCFA have differential effects of lipid metabolism, although this has mainly been demonstrated in rodent models. The major SCFA in the colon is acetate, which has been shown to up-regulate hepatic lipid synthesis <sup>(148)</sup>. Meanwhile, propionate has been reported to reduce cholesterol synthesis via inhibition of HMGR, in animal models <sup>(149)</sup>. Therefore, it is possible that dietary components which reduce the acetate-to-propionate ratio may inhibit *de novo* lipid synthesis to reduce serum lipids <sup>(150)</sup>. Different strains of bacteria produce different amounts of each type of SCFA, which may explain the differences observed in studies investigating the effects of gut-microbe-altering foods on HMGR expression. For example, *Bifidobacteria* and *Lactobacilli* do not produce butyrate <sup>(151)</sup>. *Lactobacillus rhamnosus* is capable of producing significant amounts of propionate but not either butyrate or acetate. Meanwhile, strains of *Bifidobacterium B. longum* and *B. bifidum* both produce acetate, with the latter also capable of propionate production <sup>(152)</sup>. The majority of butyrate-producing bacteria belong to the Firmicutes phylum, including the families



*Ruminococcaceae* and *Lachnospiraceae*<sup>(153)</sup>. However, the situation is likely to be more complicated since SCFA profiles remain similar between individuals despite significant inter-individual differences in gut microbiota composition, likely due to the vast overall numbers of SCFA-producing bacteria in the gut<sup>(154)</sup>.

The evidence for an effect of foods which may increase production of SCFAs on expression of hepatic HMGCR is conflicting, and reductions in plasma cholesterol may not occur solely via inhibition of cholesterol synthesis in the liver. Indeed, it has been shown that SCFAs can up-regulate expression of hepatic SREBP2 mRNA, resulting in activation of LDL-receptor gene expression and, therefore, improved circulating lipoprotein profiles via enhanced clearance of circulating LDL particles<sup>(155)</sup>. Increased expression of SREBP2 mRNA in the liver has been shown in a limited number of studies in animal models following both probiotic<sup>(77)</sup> and prebiotic supplementation<sup>(156)</sup>.

Studies investigating the mechanisms underlying the relationship between circulating bile acids and lipid CVD risk markers in response to probiotics, prebiotics and polyphenol-rich foods have been predominately conducted in animals. However, these findings are not always transferable between species. Some animals, including rats, do not have a gall bladder and thus may display differences in bile acid flow in response to food intake. This unfortunately presents a limitation of using animal models for looking at bile acid metabolism and highlights the need for more studies to be performed in humans which incorporate measures of bile acid metabolism and CVD risk.

## Conclusion

There is a growing body of evidence for a link between the consumption of probiotics, prebiotics and polyphenol-rich foods and the gut microbiota, which may be due to effects on bile acid metabolism. It has been shown that these dietary components can encourage bile acid excretion and neo-synthesis, providing a mechanism for the beneficial effects of these compounds on circulating lipid profiles. Animal model studies have demonstrated an effect of prebiotics, probiotics and polyphenol-rich foods/extracts on the FXR/FGF15 axis as well as generally increasing expression of hepatic CYP7A1 (the rate-limiting enzyme for bile acid synthesis) and potential effects on endogenous cholesterol synthesis via SREBP and HMGCR genes leading to the enhanced clearance of circulating LDL. It is evident that further research in humans is needed to fully define the relationship between diet and bile acid metabolism to determine the mechanisms behind the beneficial effects of these dietary components on host health and CVD risk. Further research could establish if circulating bile acids can be utilised as a biomarker to identify potential inflammatory and metabolic health in humans as well as which dietary components can potentially influence this relationship.

## Financial Support

R.G.P. was supported by the BBSRC (grant number BB/P028209/1) as part of the project HDHL-Biomarkers: Circulating Bile Acids as biomarkers of metabolic health -

Linking microbiota, Diet and Health (CABALA\_DIET&HEALTH), and S.A. was supported by a Kuwait Government studentship award.

## Conflict of Interest

None.

## Authorship

R.G.P. conducted the literature searches and wrote the main body of text. S.A. assisted with literature searches and compiling of tables. J.A.L. and K.G.J. participated in the concept and planning of the review as well as revision of the manuscript, and J.A.L. was responsible for the final content of the manuscript.

## Supplementary material

To view supplementary material for this article, please visit <https://doi.org/10.1017/S0954422421000081>

## References

1. Bhatnagar P, Wickramasinghe K, Williams J *et al.* (2015) The epidemiology of cardiovascular disease in the UK 2014. *Heart* **101**, 1182–1189.
2. Lewington S, Whitlock G, Clarke R *et al.* (2008) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths (vol 370, pg 1829, 2007). *Lancet* **372**.
3. Long SL, Gahan CG, Joyce SA (2017) Interactions between gut bacteria and bile in health and disease. *Mol Asp Med* **56**, 54–65.
4. Bauer E, Jakob S, Mosenthin R (2005) Principles of physiology of lipid digestion. *Asian-Australas J Anim Sci* **18**, 282–295.
5. Joyce SA, Gahan CG (2016) Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. *Annu Rev Food Sci Technol* **7**, 313–333.
6. Joyce SA, MacSharry J, Casey PG *et al.* (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. *Proc Natl Acad Sci* **111**, 7421–7426.
7. Begley M, Hill C, Gahan CGM (2006) Bile salt hydrolase activity in probiotics. *Appl Environ Microbiol* **72**, 1729–1738.
8. Chiang JY (2013) Bile acid metabolism and signaling. *Compr Physiol* **3**, 1191–1212.
9. Grover SA, Dorais M, Coupal L (2003) Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol. *Epidemiology* **14**, 315–320.
10. Li T, Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev* **66**, 948–983.
11. Staels B, Fonseca VA (2009) Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. *Diabetes Care* **32**, S237–S245.
12. Ogundare M, Theofilopoulos S, Lockhart A *et al.* (2010) Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? *J Biol Chem* **285**, 4666–4679.
13. Zheng X, Chen T, Zhao A *et al.* (2016) The brain metabolome of male rats across the lifespan. *Sci Rep* **6**, 24125.
14. Chiang JY (2009) Bile acids: regulation of synthesis. *J Lipid Res* **50**, 1955–1966.



15. Li T, Chiang JY (2012) Bile acid signaling in liver metabolism and diseases. *J Lipids* **2012**, 1–9.
16. Falany CN, Johnson MR, Barnes S *et al.* (1994) Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA: amino acid N-acyltransferase. *J Biol Chem* **269**, 19375–19379.
17. Pircher PC, Kitto JL, Petrowski ML *et al.* (2003) Farnesoid X receptor regulates bile acid-amino acid conjugation. *J Biol Chem* **278**, 27703–27711.
18. Portincasa P, Di Ciaula A, Wang HH *et al.* (2008) Coordinate regulation of gallbladder motor function in the gut-liver axis. *Hepatology* **47**, 2112–2126.
19. Russell DW (2009) Fifty years of advances in bile acid synthesis and metabolism. *J Lipid Res* **50**, S120–S125.
20. Costarelli V, Sanders T (2001) Acute effects of dietary fat composition on postprandial plasma bile acid and cholecystokinin concentrations in healthy premenopausal women. *Br J Nutr* **86**, 471–477.
21. Sato R (2010) Sterol metabolism and SREBP activation. *Arch Biochem Biophys* **501**, 177–181.
22. Janowski BA, Shan B, Russell DW (2001) The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols. *J Biol Chem* **276**, 45408–45416.
23. Eberlé D, Hegarty B, Bossard P *et al.* (2004) SREBP transcription factors: master regulators of lipid homeostasis. *Biochimie* **86**, 839–848.
24. Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. *Mol Endocrinol* **17**, 985–993.
25. Miyake JH, Doung X-DT, Strauss W *et al.* (2001) Increased production of apolipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7 $\alpha$ -hydroxylase. *J Biol Chem* **276**, 23304–23311.
26. Mertens KL, Kalsbeek A, Soeters MR *et al.* (2017) Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. *Front Neurosci* **11**, 617.
27. Staley C, Weingarden AR, Khoruts A *et al.* (2017) Interaction of gut microbiota with bile acid metabolism and its influence on disease states. *Appl Microbiol Biotechnol* **101**, 47–64.
28. Ridlon JM, Harris SC, Bhowmik S *et al.* (2016) Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* **7**, 22–39.
29. Lefebvre P, Cariou B, Lien F *et al.* (2009) Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* **89**, 147–191.
30. Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH *et al.* (2018) Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. *Biomolecules* **8**, 159.
31. Wahlström A, Sayin SI, Marschall H-U *et al.* (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metab* **24**, 41–50.
32. Li T, Chiang JY (2015) Bile acids as metabolic regulators. *Curr Opin Gastroenterol* **31**, 159.
33. Hylemon PB, Zhou H, Pandak WM *et al.* (2009) Bile acids as regulatory molecules. *J Lipid Res* **50**, 1509–1520.
34. Cariou B, Staels B (2007) FXR: a promising target for the metabolic syndrome? *Trends Pharmacol Sci* **28**, 236–243.
35. Chen X, Lou G, Meng Z *et al.* (2011) TGR5: a novel target for weight maintenance and glucose metabolism. *Exp Diabetes Res* **2011**, 1–5.
36. Watanabe M, Houten SM, Matakai C *et al.* (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* **439**, 484.
37. Thomas C, Gioiello A, Noriega L *et al.* (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* **10**, 167–177.
38. Devkota S, Wang Y, Musch MW *et al.* (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10 $^{-/-}$  mice. *Nature* **487**, 104.
39. Yoshimoto S, Loo TM, Atarashi K *et al.* (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* **499**, 97.
40. Albaugh VL, Flynn CR, Cai S *et al.* (2015) Early increases in bile acids post Roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids. *J Clin Endocrinol Metab* **100**, E1225–E1233.
41. Basso N, Soricelli E, Castagneto-Gissey L *et al.* (2016) Insulin resistance, microbiota and fat distribution changes by a new model of vertical sleeve gastrectomy in obese rats. *Diabetes*, **65**, 2990–3001.
42. Fouladi F, Mitchell JE, Wonderlich JA *et al.* (2016) The contributing role of bile acids to metabolic improvements after obesity and metabolic surgery. *Obes Surg* **26**, 2492–2502.
43. Murakami M, Une N, Nishizawa M *et al.* (2013) Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. *Springerplus* **2**, 20.
44. Mahmoud AAA, Elshazly SM (2014) Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. *PLoS One* **9**, e106993.
45. Wu T, Bound MJ, Standfield SD *et al.* (2013) Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. *J Clin Endocrinol Metab* **98**, E718–E722.
46. Sayin SI, Wahlström A, Felin J *et al.* (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* **17**, 225–235.
47. Joyce SA, Gahan CGM (2014) The gut microbiota and the metabolic health of the host. *Curr Opin Gastroenterol* **30**, 120–127.
48. Chen M-L, Yi L, Zhang Y *et al.* (2016) Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. *MBio* **7**, e02210–e02215.
49. Koutsos A, Tuohy K, Lovegrove J (2015) Apples and cardiovascular health—is the gut microbiota a core consideration? *Nutrients* **7**, 3959–3998.
50. Arora T, Singh S, Sharma RK (2013) Probiotics: interaction with gut microbiome and antiobesity potential. *Nutrition* **29**, 591–596.
51. Jones BV, Begley M, Hill C *et al.* (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. *Proc Natl Acad Sci* **105**, 13580–13585.
52. Ikeda I, Imasato Y, Sasaki E *et al.* (1992) Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats. *Biochim Biophys Acta Lipids Lipid Metab* **1127**, 141–146.
53. Ikeda I, Yamahira T, Kato M *et al.* (2010) Black-tea polyphenols decrease micellar solubility of cholesterol in vitro and intestinal absorption of cholesterol in rats. *J Agric Food Chem* **58**, 8591–8595.
54. Watanabe M, Morimoto K, Houten SM *et al.* (2012) Bile acid binding resin improves metabolic control through the induction of energy expenditure. *PLoS One* **7**, e38286.
55. Matsuoka K, Kanai T (2015) The gut microbiota and inflammatory bowel disease. *Semin Immunopathol* **37**, 47–55.





56. Sokol H, Lay C, Seksik P *et al.* (2008) Analysis of bacterial bowel communities of IBD patients: what has it revealed? *Inflamm Bowel Dis* **14**, 858–867.
57. Duboc H, Rajca S, Rainteau D *et al.* (2013) Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. *Gut* **62**, 531–539.
58. Zheng X, Huang F, Zhao A *et al.* (2017) Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. *BMC Biol* **15**, 1–15.
59. Sannasiddappa TH, Lund PA, Clarke SR (2017) In vitro antibacterial activity of unconjugated and conjugated bile salts on *Staphylococcus aureus*. *Front Microbiol* **8**, 1581.
60. Chen J, Thomsen M, Vitetta L (2019) Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. *J Cell Biochem* **120**, 2713–2720.
61. Carding S, Verbeke K, Vipond DT *et al.* (2015) Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis* **26**, 26191.
62. Öner Ö, Aslim B, Aydağ SB (2014) Mechanisms of cholesterol-lowering effects of lactobacilli and bifidobacteria strains as potential probiotics with their bsh gene analysis. *J Mol Microbiol Biotechnol* **24**, 12–18.
63. Costabile A, Buttarazzi I, Kolida S *et al.* (2017) An in vivo assessment of the cholesterol-lowering efficacy of *Lactobacillus plantarum* ECGC 13110402 in normal to mildly hypercholesterolaemic adults. *PLoS One* **12**, e0187964.
64. Costabile A, Klinder A, Fava F *et al.* (2008) Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. *Br J Nutr* **99**, 110–120.
65. Wa Y, Yin B, Gu R *et al.* (2019) Effects of single probiotic and combined probiotic-fermented milk on lipid metabolism in hyperlipidemic rats. *Front Microbiol* **10**, 1312.
66. Ma C, Zhang S, Lu J *et al.* (2019) Screening for cholesterol-lowering probiotics from lactic acid bacteria isolated from corn silage based on three hypothesized pathways. *Int J Mol Sci* **20**, 2073.
67. Huang F, Zhang F, Xu D *et al.* (2018) *Enterococcus faecium* WEFA23 from infants lessens high-fat-diet-induced hyperlipidemia via cholesterol 7- $\alpha$ -hydroxylase gene by altering the composition of gut microbiota in rats. *J Dairy Sci* **101**, 7757–7767.
68. Guo L, Li T, Tang Y *et al.* (2016) Probiotic properties of *Enterococcus* strains isolated from traditional naturally fermented cream in China. *Microb Biotechnol* **9**, 737–745.
69. Wang DQ-H, Wang HH, Portincasa P (2019) Update on the molecular mechanisms underlying the effect of cholecystokinin and cholecystokinin-1 receptor on the formation of cholesterol gallstones. *Curr Med Chem*.
70. Pato U, Surono IS, Hosono A (2004) Hypocholesterolemic effect of indigenous *Lactobacillus* acid bacteria by deconjugation of bile salts. *Asian-Australas J Anim Sci* **17**, 1741–1745.
71. Jeun J, Kim S, Cho S-Y *et al.* (2010) Hypocholesterolemic effects of *Lactobacillus plantarum* KCTC3928 by increased bile acid excretion in C57BL/6 mice. *Nutrition* **26**, 321–330.
72. Guo Z, Liu X, Zhang Q *et al.* (2011) Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. *Nutr Metab Cardiovasc Dis* **21**, 844–850.
73. Jones ML, Martoni CJ, Parent M *et al.* (2012) Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active *Lactobacillus reuteri* NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. *Br J Nutr* **107**, 1505–1513.
74. Martoni CJ, Labbé A, Ganopolsky JG *et al.* (2015) Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active *L. reuteri* NCIMB 30242. *Gut Microbe* **6**, 57–65.
75. Zhai Q, Liu Y, Wang C *et al.* (2019) *Lactobacillus plantarum* CCFM8661 modulates bile acid enterohepatic circulation and increases lead excretion in mice. *Food Funct* **10**, 1455–1464.
76. Michael D, Davies T, Moss J *et al.* (2017) The anti-cholesterolaemic effect of a consortium of probiotics: an acute study in C57BL/6J mice. *Sci Rep* **7**, 1–10.
77. Damodharan K, Lee YS, Palaniyandi SA *et al.* (2015) Preliminary probiotic and technological characterization of *Pediococcus pentosaceus* strain KID7 and in vivo assessment of its cholesterol-lowering activity. *Front Microbiol* **6**, 768.
78. Degirolamo C, Rainaldi S, Bovenga F *et al.* (2014) Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. *Cell Rep* **7**, 12–18.
79. Stadlbauer V, Leber B, Lemesch S *et al.* (2015) *Lactobacillus casei* Shirota supplementation does not restore gut microbiota composition and gut barrier in metabolic syndrome: a randomized pilot study. *PLoS One* **10**, e0141399.
80. Oshiro T, Nagata S, Wang C *et al.* (2019) Bifidobacterium supplementation of colostrum and breast milk enhances weight gain and metabolic responses associated with microbiota establishment in very-preterm infants. *Biomed Hub* **4**, 1–10.
81. Gibson GR, Hutkins R, Sanders ME *et al.* (2017) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* **14**, 491.
82. Figueroa-González I, Quijano G, Ramírez G *et al.* (2011) Probiotics and prebiotics—perspectives and challenges. *J Sci Food Agric* **91**, 1341–1348.
83. Swanson K, de Vos W, Martens E *et al.* (2020) Effect of fructans, prebiotics and fibres on the human gut microbiome assessed by 16S rRNA-based approaches: a review. *Benef Microbes* **11**, 101–129.
84. Wang Y, Harding SV, Thandapilly SJ *et al.* (2017) Barley  $\beta$ -glucan reduces blood cholesterol levels via interrupting bile acid metabolism. *Br J Nutr* **118**, 822–829.
85. Nicolucci AC, Hume MP, Martínez I *et al.* (2017) Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. *Gastroenterology* **153**, 711–722.
86. Cronin BE, Allsopp PJ, Slevin MM *et al.* (2016) Effects of supplementation with a calcium-rich marine-derived multi-mineral supplement and short-chain fructo-oligosaccharides on serum lipids in postmenopausal women. *Br J Nutr* **115**, 658–665.
87. Meneses ME, Martínez-Carrera D, Torres N *et al.* (2016) Hypocholesterolemic properties and prebiotic effects of Mexican *Ganoderma lucidum* in C57BL/6 mice. *PLoS One* **11**, e0159631.
88. Santos J, Espadaler J, Mancebo R *et al.* (2012) Selective in vivo effect of chitosan on fatty acid, neutral sterol and bile acid excretion: a longitudinal study. *Food Chem* **134**, 940–947.
89. Mandimika T, Paturi G, De Guzman CE *et al.* (2012) Effects of dietary broccoli fibre and corn oil on serum lipids, faecal bile acid excretion and hepatic gene expression in rats. *Food Chem* **131**, 1272–1278.
90. Gunness P, Michiels J, Vanhaecke L *et al.* (2016) Reduction in circulating bile acid and restricted diffusion across the intestinal epithelium are associated with a decrease in blood cholesterol in the presence of oat  $\beta$ -glucan. *FASEB J* **30**, 4227–4238.

91. Ellegård L, Andersson H (2007) Oat bran rapidly increases bile acid excretion and bile acid synthesis: an ileostomy study. *Euro J Clin Nutr* **61**, 938–945.
92. Drzikova B, Dongowski G, Gebhardt E (2005) Dietary fibre-rich oat-based products affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in rats. *Br J Nutr* **94**, 1012–1025.
93. Chen H-L, Cheng H-C, Wu W-T *et al.* (2008) Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults: a placebo-controlled, diet-controlled trial. *J Am Coll Nutr* **27**, 102–108.
94. Hijová E, Bomba A, Bertková I *et al.* (2012) Prebiotics and bio-active natural substances induce changes of composition and metabolic activities of the colonic microflora in cancerous rats. *Acta Biochim Pol* **59**.
95. Lærke HN, Pedersen C, Mortensen MA *et al.* (2008) Rye bread reduces plasma cholesterol levels in hypercholesterolaemic pigs when compared to wheat at similar dietary fibre level. *J Sci Food Agric* **88**, 1385–1393.
96. Sobko T, Reinders C, Jansson E *et al.* (2005) Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite. *Nitric Oxide* **13**, 272–278.
97. Catry E, Bindels LB, Tailleux A *et al.* (2018) Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. *Gut* **67**, 271–283.
98. Hervet-Hernández D, Goñi I (2011) Dietary polyphenols and human gut microbiota: a review. *Food Rev Int* **27**, 154–169.
99. Holt RR, Heiss C, Kelm M *et al.* (2012) The potential of flavanol and procyanidin intake to influence age-related vascular disease. *J Nutr Gerontol Geriatr* **31**, 290–323.
100. Zhang L, Wang Y, Li D *et al.* (2016) The absorption, distribution, metabolism and excretion of procyanidins. *Food Funct* **7**, 1273–1281.
101. Koutsos A, Lima M, Conterno L *et al.* (2017) Effects of commercial apple varieties on human gut microbiota composition and metabolic output using an in vitro colonic model. *Nutrients* **9**, 533.
102. Sembries S, Dongowski G, Mehrländer K *et al.* (2006) Physiological effects of extraction juices from apple, grape, and red beet pomaces in rats. *J Agric Food Chem* **54**, 10269–10280.
103. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M *et al.* (2012) Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. *Am J Clin Nutr* **95**, 1323–1334.
104. Wallace AJ, Eady SL, Hunter DC *et al.* (2015) No difference in fecal levels of bacteria or short chain fatty acids in humans, when consuming fruit juice beverages containing fruit fiber, fruit polyphenols, and their combination. *Nutr Res* **35**, 23–34.
105. Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. *J Nutr* **130**, 2073S–2085S.
106. Kemperman RA, Bolca S, Roger LC *et al.* (2010) Novel approaches for analysing gut microbes and dietary polyphenols: challenges and opportunities. *Microbiology* **156**, 3224–3231.
107. Patti AM, Toth PP, Giglio VR *et al.* (2017) Nutraceuticals as an important part of combination therapy in dyslipidaemia. *Curr Pharm Des* **23**, 2496–2503.
108. Naumann S, Haller D, Eisner P *et al.* (2020) Mechanisms of interactions between bile acids and plant compounds—a review. *Int J Mol Sci* **21**, 6495.
109. Huang J, Feng S, Liu A *et al.* (2018) Green tea polyphenol EGCG alleviates metabolic abnormality and fatty liver by decreasing bile acid and lipid absorption in mice. *Mol Nutr Food Res* **62**, 1700696.
110. Ogawa K, Hirose S, Nagaoka S *et al.* (2016) Interaction between tea polyphenols and bile acid inhibits micellar cholesterol solubility. *J Agric Food Chem* **64**, 204–209.
111. Adisakwattana S, Moonrat J, Srichairat S *et al.* (2010) Lipid-lowering mechanisms of grape seed extract (*Vitis vinifera* L.) and its antihyperlipidemic activity. *J Med Plant Res* **4**, 2113–2120.
112. Ngamukote S, Mäkinen K, Thilawech T *et al.* (2011) Cholesterol-lowering activity of the major polyphenols in grape seed. *Molecules* **16**, 5054–5061.
113. Koutsos A, Riccadonna S, Ulaszewska MM *et al.* (2020) Two apples a day lower serum cholesterol and improve cardiometabolic biomarkers in mildly hypercholesterolemic adults: a randomized, controlled, crossover trial. *Am J Clin Nutr* **111**, 307–318.
114. Fujita H, Yamagami T (2008) Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. *Nutr Res* **28**, 450–456.
115. Velasquez M, Ramezani A, Manal A *et al.* (2016) Trimethylamine N-oxide: the good, the bad and the unknown. *Toxins* **8**, 326.
116. Senthong V, Li XS, Hudec T *et al.* (2016) Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. *J Am Coll Cardiol* **67**, 2620–2628.
117. Koeth RA, Wang Z, Levison BS *et al.* (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* **19**, 576.
118. Aprikian O, Buserrolles Jm, Manach C *et al.* (2002) Lyophilized apple counteracts the development of hypercholesterolemia, oxidative stress, and renal dysfunction in obese Zucker rats. *J Nutr* **132**, 1969–1976.
119. Ravn-Haren G, Krath BN, Markowski J *et al.* (2018) Apple pomace improves gut health in Fisher rats independent of seed content. *Food Funct* **9**, 2931–2941.
120. Chavez-Santoscoy RA, Gutierrez-Urbe JA, Granados O *et al.* (2014) Flavonoids and saponins extracted from black bean (*Phaseolus vulgaris* L.) seed coats modulate lipid metabolism and biliary cholesterol secretion in C57BL/6 mice. *Br J Nutr* **112**, 886–899.
121. Mathew B, Yoseph B, Dessale T *et al.* (2012) Hypolipidaemic effect of leucodelphinidin derivative from *Ficus bengalensis* Linn on cholesterol fed rats. *Res J Chem Sci*, ISSN **2231**, 606X.
122. Feng D, Sun J-g, Sun R-b *et al.* (2015) Isoflavones and phytochemicals contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice. *Acta Pharmacol Sin* **36**, 1462–1472.
123. Lee Y-N, Hsu G-SW, Lin W-T *et al.* (2016) Hypolipidemic and antioxidative effects of *Glossogyne tenuifolia* in hamsters fed an atherogenic diet. *J Med Food* **19**, 513–517.
124. Gong J, Peng C, Chen T *et al.* (2010) Effects of theabrownin from Pu-erh tea on the metabolism of serum lipids in rats: mechanism of action. *J Food Sci* **75**, H182–H189.
125. Miura D, Miura Y, Yagasaki K (2003) Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. *Life Sci* **73**, 1393–1400.
126. Wang D, Xia M, Gao S *et al.* (2012) Cyanidin-3-O- $\beta$ -glucoside upregulates hepatic cholesterol 7 $\alpha$ -hydroxylase expression and reduces hypercholesterolemia in mice. *Mol Nutr Food Res* **56**, 610–621.
127. Ushiroda C, Naito Y, Takagi T *et al.* (2019) Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice. *J Clin Biochem Nutr*, 18–116.

128. Hoang M-H, Jia Y, Mok B *et al.* (2015) Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor- $\beta$ . *J Nutr Biochem* **26**, 868–875.
129. Zhang M, Xie Z, Gao W *et al.* (2016) Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats. *Nutr Res* **36**, 271–279.
130. Daniel RS, Devi K, Augusti K *et al.* (2003) Mechanism of action of antiatherogenic and related effects of *Ficus bengalensis* Linn. flavonoids in experimental animals.
131. Guo J, Han X, Tan H *et al.* (2019) Blueberry extract improves obesity through regulation of the gut microbiota and bile acids via pathways involving FXR and TGR5. *iScience* **19**, 676–690.
132. Anhê FF, Nachbar RT, Varin TV *et al.* (2019) Treatment with camu camu (*Myrciaria dubia*) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice. *Gut* **68**, 453–464.
133. Spiller GA, Story JA, Lodi TA *et al.* (2003) Effect of sun-dried raisins on bile acid excretion, intestinal transit time, and fecal weight: a dose–response study. *J Med Food* **6**, 87–91.
134. Williamson G, Carughi A (2010) Polyphenol content and health benefits of raisins. *Nutr Res* **30**, 511–519.
135. Mai V, Katki HA, Harmsen H *et al.* (2004) Effects of a controlled diet and black tea drinking on the fecal microflora composition and the fecal bile acid profile of human volunteers in a double-blinded randomized feeding study. *J Nutr* **134**, 473–478.
136. Inagaki T, Choi M, Moschetta A *et al.* (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* **2**, 217–225.
137. Chen J, Huang X-F (2009) The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. *J Clin Lipidol* **3**, 154–158.
138. Theuvsen E, Mensink RP (2007) Simultaneous intake of  $\beta$ -glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. *J Nutr* **137**, 583–588.
139. Hirsova P, Karlasova G, Dolezelova E *et al.* (2013) Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2. *Toxicology* **303**, 9–15.
140. Watanabe M, Ayugase J (2010) Effects of buckwheat sprouts on plasma and hepatic parameters in type 2 diabetic db/db mice. *J Food Sci* **75**, H294–H299.
141. Jiao R, Zhang Z, Yu H *et al.* (2010) Hypocholesterolemic activity of grape seed proanthocyanidin is mediated by enhancement of bile acid excretion and up-regulation of CYP7A1. *J Nutr Biochem* **21**, 1134–1139.
142. Heidker RM, Caiozzi GC, Ricketts ML (2016) Dietary procyanidins selectively modulate intestinal farnesoid X receptor-regulated gene expression to alter enterohepatic bile acid recirculation: elucidation of a novel mechanism to reduce triglyceridemia. *Mol Nutr Food Res* **60**, 727–736.
143. Downing LE, Heidker RM, Caiozzi GC *et al.* (2015) A grape seed procyanidin extract ameliorates fructose-induced hypertriglyceridemia in rats via enhanced fecal bile acid and cholesterol excretion and inhibition of hepatic lipogenesis. *PLoS One* **10**, e0140267.
144. Quifer-Rada P, Choy YY, Calvert CC *et al.* (2016) Use of metabolomics and lipidomics to evaluate the hypocholesterolemic effect of proanthocyanidins from grape seed in a pig model. *Mol Nutr Food Res* **60**, 2219–2227.
145. Wang G, Huang W, Xia Y *et al.* (2019) Cholesterol-lowering potentials of *Lactobacillus* strain overexpression of bile salt hydrolase on high cholesterol diet-induced hypercholesterolemic mice. *Food Funct* **10**, 1684–1695.
146. Hara H, Haga S, Aoyama Y *et al.* (1999) Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine. *J Nutr* **129**, 942–948.
147. Mueller NT, Zhang M, Juraschek SP *et al.* (2020) Effects of high-fiber diets enriched with carbohydrate, protein, or unsaturated fat on circulating short chain fatty acids: results from the OmniHeart randomized trial. *Am J Clin Nutr* **111**, 545–554.
148. Fushimi T, Suruga K, Oshima Y *et al.* (2006) Dietary acetic acid reduces serum cholesterol and triacylglycerols in rats fed a cholesterol-rich diet. *Br J Nutr* **95**, 916–924.
149. Wright RS, Anderson JW, Bridges SR (1990) Propionate inhibits hepatocyte lipid synthesis. *Proc Soc Exp Biol Med* **195**, 26–29.
150. Wong JM, De Souza R, Kendall CW *et al.* (2006) Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* **40**, 235–243.
151. Zampa A, Silvi S, Fabiani R *et al.* (2004) Effects of different digestible carbohydrates on bile acid metabolism and SCFA production by human gut micro-flora grown in an in vitro semi-continuous culture. *Anaerobe* **10**, 19–26.
152. LeBlanc JG, Chain F, Martin R *et al.* (2017) Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. *Microb Cell Fact* **16**, 79.
153. Geirnaert A, Calatayud M, Grootaert C *et al.* (2017) Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. *Sci Rep* **7**, 1–14.
154. Reichardt N, Vollmer M, Holtrop G *et al.* (2018) Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production. *ISME J* **12**, 610–622.
155. Zhao Y, Liu J, Hao W *et al.* (2017) Structure-specific effects of short-chain fatty acids on plasma cholesterol concentration in male Syrian hamsters. *J Agric Food Chem* **65**, 10984–10992.
156. Parnell JA, Reimer RA (2010) Effect of prebiotic fibre supplementation on hepatic gene expression and serum lipids: a dose–response study in JCR:LA-cp rats. *Br J Nutr* **103**, 1577–1584.
157. Heuman D, Hylemon P, Vlahcevic Z (1989) Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. *J Lipid Res* **30**, 1161–1171.
158. Maruyama T, Miyamoto Y, Nakamura T *et al.* (2002) Identification of membrane-type receptor for bile acids (M-BAR). *Biochem Biophys Res Commun* **298**, 714–719.
159. Chen J, Raymond K (2006) Nuclear receptors, bile-acid detoxification, and cholestasis. *Lancet* **367**, 454–456.
160. Makishima M, Lu TT, Xie W *et al.* (2002) Vitamin D receptor as an intestinal bile acid sensor. *Science* **296**, 1313–1316.
161. Owen BM, Milona A, van Mil S *et al.* (2010) Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid. *Drug Metab Dispos* **38**, 143–149.
162. Sato H, Macchiarulo A, Thomas C *et al.* (2008) Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure–activity relationships, and molecular modeling studies. *J Med Chem* **51**, 1831–1841.
163. Song C, Hiipakka RA, Liao S (2000) Selective activation of liver X receptor alpha by 6 $\alpha$ -hydroxy bile acids and analogs. *Steroids* **65**, 423–427.
164. Hong J, Behar J, Wands J *et al.* (2010) Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. *Gut* **59**, 170–180.

165. Han J, Liu Y, Wang R *et al.* (2015) Metabolic profiling of bile acids in human and mouse blood by LC–MS/MS in combination with phospholipid-depletion solid-phase extraction. *Anal Chem* **87**, 1127–1136.
166. Ginos BN, Navarro SL, Schwarz Y *et al.* (2018) Circulating bile acids in healthy adults respond differently to a dietary pattern characterized by whole grains, legumes and fruits and vegetables compared to a diet high in refined grains and added sugars: a randomized, controlled, crossover feeding study. *Metabolism* **83**, 197–204.
167. Wu W-T, Cheng H-C, Chen H-L (2011) Ameliorative effects of konjac glucomannan on human faecal  $\beta$ -glucuronidase activity, secondary bile acid levels and faecal water toxicity towards Caco-2 cells. *Br J Nutr* **105**, 593–600.
168. Chaplin M, Chaudhury S, Dettmar P *et al.* (2000) Effect of ispaghula husk on the faecal output of bile acids in healthy volunteers. *J Steroid Biochem Mol Biol* **72**, 283–292.
169. Martín-Peláez S, Mosele JI, Pizarro N *et al.* (2017) Effect of virgin olive oil and thyme phenolic compounds on blood lipid profile: implications of human gut microbiota. *Euro J Nutr* **56**, 119–131.
170. Tzounis X, Rodriguez-Mateos A, Vulevic J *et al.* (2011) Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. *The American journal of clinical nutrition* **93**, 62–72.
171. Choi I-D, Kim S-H, Jeong J-W *et al.* (2016) Triglyceride-Lowering effects of two probiotics, *Lactobacillus plantarum* KY1032 and *Lactobacillus curvatus* HY7601, in a rat model of high-fat diet-induced hypertriglyceridemia. *Journal of microbiology and biotechnology* **26**, 483–487.
172. Zhou J, Tang L, Shen C-L *et al.* (2018) Green tea polyphenols modify gut-microbiota dependent metabolisms of energy, bile constituents and micronutrients in female Sprague–Dawley rats. *J Nutr Biochem* **61**, 68–81.
173. Xie M, Chen G, Wan P *et al.* (2018) Effects of dicaffeoylquinic acids from *Ilex kudingcha* on lipid metabolism and intestinal microbiota in high-fat-diet-fed mice. *J Agric Food Chem* **67**, 171–183.
174. del Bas JM, Crescenti A, Arola-Arnal A *et al.* (2015) Intake of grape procyanidins during gestation and lactation impairs reverse cholesterol transport and increases atherogenic risk indexes in adult offspring. *J Nutr Biochem* **26**, 1670–1677.
175. Sheng L, Jena PK, Liu H-X *et al.* (2018) Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched *Akkermansia muciniphila*. *FASEB J* **32**, 6371–6384.
176. Salazar N, Neyrinck AM, Bindels LB *et al.* (2019) Functional effects of EPS-producing *Bifidobacterium* administration on energy metabolic alterations of diet-induced obese mice. *Front Microbiol* **10**, 1809.
177. Natividad JM, Lamas B, Pham HP *et al.* (2018) *Bilophila wadsworthia* aggravates high fat diet induced metabolic dysfunctions in mice. *Nat Commun* **9**, 1–15.
178. Kuo S-M, Merhige PM, Hagey LR (2013) The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10<sup>−/−</sup> mice. *PLoS One* **8**.
179. Liu Y, Chen K, Li F *et al.* (2020) Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. *Hepatology* 2050.
180. de Almeida Jackix E, Monteiro EB, Raposo HF *et al.* (2013) Taioba (*Xanthosoma sagittifolium*) leaves: nutrient composition and physiological effects on healthy rats. *J Food Sci* **78**, H1929–H1934.
181. Dongowski G, Jacobasch G, Schmiedl D (2005) Structural stability and prebiotic properties of resistant starch type 3 increase bile acid turnover and lower secondary bile acid formation. *J Agric Food Chem* **53**, 9257–9267.
182. Villanueva-Suárez M-J, Pérez-Cózar M-L, Mateos-Aparicio I *et al.* (2016) Potential fat-lowering and prebiotic effects of enzymatically treated okara in high-cholesterol-fed Wistar rats. *Int J Food Sci Nutr* **67**, 828–833.
183. Gunness P, Williams BA, Gerrits WJ *et al.* (2016) Circulating triglycerides and bile acids are reduced by a soluble wheat arabinoxylan via modulation of bile concentration and lipid digestion rates in a pig model. *Mol Nutr Food Res* **60**, 642–651.